Stereoselective Synthesis of 2-Oxyenamides

Sara-Cathrin Krieg,^{‡[a]} Jennifer Grimmer,^{‡[a]}, Annika Maria Pick^[a], Harlad Kelm^[a], Martin Breugst,^[b,c] Georg Manolikakes^[a]*

- [a] Department of Organic Chemistry, Technical University Kaiserslautern
 Erwin-Schrödinger-Str. Geb. 54,
 67663 Kaiserslautern, Germany
 E-mail: manolikakes@chemie.uni-kl.de
 https://www.chemie.uni-kl.de/manolikakes
- [b] Prof. Dr. M. Breugst
 Department of Chemistry, University of Cologne
 Greinstraße 4, 50939 Köln, Germany
 Email: <u>mbreugst@uni-koeln.de</u>
- [c] Prof. Dr. M. Breugst
 Institut f
 ür Chemie, TU Chemnitz
 Straße der Nationen 62, 09111 Chemnitz, Germany
 Email: martin.breugst@chemie.tu-chemnitz.de

SUPPORTING INFORMATION

1	Gei	neral Information	. 2
2	Pre	paration and analytical data	. 4
	2.1	Amides	. 4
	2.2	Aldehydes	14
	2.3	(Z)-Oxyenamides/(Z)-oxyencarbamates	19
	2.4	(Z)-Enol sulfonates	38
	2.5	2-Oxyenimides	40
	2.6	N-Methylated 2-oxyenamide	45
3	Cor	nputational Details	49
4	NMR Data		50
5	Xra	y1	21
6	Ref	erences1	25

1 GENERAL INFORMATION

EXPERIMENTAL METHODS. Unless otherwise mentioned, all reactions were carried out without any precautions to exclude ambient air or moisture. All yields refer to isolated yields of compounds estimated to be > 95% pure as determined by ¹H-NMR.

CHROMATOGRAPHY. Flash column chromatography was performed using a puriflash XS 420+ Flash purifier machine from Interchim with prepacked flash columns (Puriflash_SilicaHP_15µm_F0012, Puriflash_SilicaHP_15µm_F0025 or Puriflash_SilicaHP_15µm_F0040) and the respectively specified solvent mixture. *Column chromatography* was performed with Silica 60 (0.04-0.063 mm, 230-400 mesh) and the specified solvent mixture. *Thin layer chromatography* was performed on aluminum sheets coated with SiO₂ (TLC silica gel 60 F254). The spots were visualized by ultraviolet light, iodine, cerium ammonium molybdate (CAM) or KMnO₄.

SOLVENTS. Solvents for reactions and column chromatography were obtained from different commercial suppliers in >97% purity and used as received. Solvents for column chromatography were technical standard.

MATERIALS. All starting materials obtained from commercial sources were used without further purification.

ANALYTICAL DATA AND INSTRUMENTATION.

NMR SPECTROSCOPY. Proton nuclear magnetic resonance spectra (¹H NMR), carbon spectra (¹³C NMR) and fluorine (¹⁹F NMR) were recorded at 400 or 600 MHz (¹H), 101 or 151 MHz (¹³C) and 376 MHz (¹⁹F), respectively. Chemical shifts are reported as δ - values relative to the residual CDCl₃ (δ = 7.26 ppm for ¹H and δ = 77.16 ppm for ¹³C), DMSO-d⁶ (δ = 2.50 ppm for 1H and δ = 39.51 ppm for ¹³C). Coupling constants (J) are given in Hz and multiplicities of the signals are abbreviated as follows: s = singlet; d = doublet; t = triplet; q = quartet; sp = septet; m = multiplet; dd = doublet of doublets and dt = doublet of triplets dqd = doublet of quartets of doublets.

MELTING POINTS. Melting points are reported uncorrected.

MASS SPECTROMETRY. Mass spectra (MS) were measured on an Advion Mass Express (expression-LCMS) using electrospray ionization (ESI) techniques. High resolution mass spectra were acquired on a Waters GCT Premium using electron ionization mass spectroscopy (EI-MS-TOF).

INFRARED SPECTROSCOPY. Infrared spectra (IR) of neat substances were recorded on a Shimadzu IRSpirit (QATR-S). The absorption bands are reported in wave numbers (cm⁻¹).

E:Z RATIO. The *E:Z* ratios were determined via ¹H-NMR analysis of the unpurified product after aqueous workup and after isolation via column chromatography. An *E:Z* ratio of <2:98 indicates that no minor isomer was observed by ¹H NMR. Yields refer to isolated yields of the analytically pure oxyenamides. If the second isomer could be isolated, a combined yield is given in addition.

.

2 PREPARATION AND ANALYTICAL DATA

2.1 Amides

GENERAL PROCEDURE 1 (GP1)



To a solution of 2,2-dimethoxyethanamine (2.12 mL, 20.0 mmol, 1.0 equiv) and Et_3N (12.6 mL, 60.0 mmol, 3.0 equiv) in CH_2CI_2 (30 mL) was added dropwise the corresponding acyl chloride (22.0 mmol, 1.1 equiv) at 0 °C. After stirring for 30 min at 0°C, the reaction was quenched with saturated aqueous NH_4CI (20 mL) and the mixture was extracted with CH_2CI_2 (3x 20 mL). The combined organic layers were dried over Na_2SO_4 , filtered and concentrated in vacuo. Purification of the crude residue by flash column chromatography afforded the analytically pure product.^[1]

2.1.1 N-(2,2-Dimethoxyethyl)benzamide 5a



5a

Prepared according to **GP1** from 2,2-dimethoxyethanamine (5.50 mL, 50.0 mmol, 1.0 equiv), Et₃N (21.0 mL, 150 mmol, 3.0 equiv) and benzoylchloride (6.406 mL, 55.0 mmol, 1.1 equiv) in CH₂Cl₂ (85 mL). Purification by column chromatography (*n*-hexane:EtOAc = 7:3 \rightarrow 1:1) afforded *N*-(2,2-dimethoxyethyl)benzamide **5a** as a colorless solid (10.4 g, 99%). Analytical data is in accordance with the literature.^[1]

R_f (*n*-hexane:EtOAc = 1:1) 0.33.

m.p. 54-56 °C

¹**H NMR** (400 MHz, CDCl₃) δ 7.88 – 7.58 (m, 2H), 7.49 (d, J = 7.4 Hz, 1H), 7.47 – 7.40 (m, 2H), 6.36 (s, 1H), 4.48 (d, J = 5.2 Hz, 1H), 3.61 (t, J = 5.5 Hz, 2H), 3.43 (s, 6H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 167.7, 134.5, 131.7, 128.0, 127.1, 102.9, 54.8, 41.6.

MS (ESI) m/z calcd for $C_{11}H_{15}NO_3Na^+$ 232.1 [M+Na]⁺, found 232.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{11}H_{15}NO_3$ 209.1052 [M]⁺, found 209.1052 [M]⁺.

IR (v in cm⁻¹): 3345 (w), 3308 (w), 2937 (w), 1632 (m), 1542 (s), 1428 (w), 1327 (m), 1340 (m), 1128 (s), 1110 (s), 1068 (s), 1018 (m), 960 (m), 885 (w), 796 (m), 693 (m), 658 (s).

2.1.2 Tert-butyl (2,2-dimethoxyethyl)carbamate **5b**



Prepared according to **GP1** from 2,2-dimethoxyethanamine (1.6 mL, 15.0 mmol, 1.0 equiv), Et₃N (6.24 mL, 45.0 mmol, 3.0 equiv) and di-*tert*-butyldicarbonat (3.53 mL, 16.5 mmol, 1.1 equiv) in CH_2Cl_2 (30 mL). Aqueous work up afforded *tert*-butyl (2,2-dimethoxyethyl)carbamate **5b** as a colorless liquid (2.96 g, 96%). %). Analytical data is in accordance with the literature.^[2]

R_f (*n*-hexane:EtOAc = 4:1) 0.42.

¹**H NMR** (400 MHz, CDCl₃) δ 4.72 (s, 1H), 4.36 (t, J = 5.4 Hz, 1H), 3.38 (s, 6H), 3.25 (t, J = 5.7 Hz, 2H), 1.44 (s, 9H).

¹³**C NMR** (101 MHz, CDCl₃) δ 156.0, 103.1, 79.6, 54.4, 42.2, 28.5.

MS (ESI) m/z calcd for $C_9H_{19}NO_4Na^+ 228.1 \text{ [M+Na]}^+$, found 228.2 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_9H_{19}NO_4$ 205.1314 [M]⁺, found 2005.1313 [M]⁺.

IR (v in cm⁻¹): 3358 (w), 2977 (w), 2936 (w), 1712 (s), 1515 (m), 1455 (w), 1391 (w), 1365 (m), 1249 (m), 1171 (s), 1126 (s), 1061 (s), 949 (m),, 873 (w), 780 (w), 765 (w). 545 (w).

2.1.3 Benzyl (2,2-dimethoxyethyl)carbamate 5c



Prepared according to literature.^[3]

To a solution of 2,2-dimethoxyethylamine (1.6 mL, 15.0 mmol) in Et₂O (75 mL) was added K₂CO₃ (6.20 g, 44.9 mmol) and water (75 mL). The reaction mixture was cooled to 0 °C and benzyl chloroformate (2.1 mL, 15.0 mmol) was added dropwise. The reaction mixture was allowed to warm to rt and stirred for 16 h. The two layers were separated and the aqueous layer was extracted with Et₂O (2 × 50 mL). The combined organic layers were washed with 5% aqueous citric acid (3 × 80 mL) and brine (2 × 80 mL), dried over Na₂SO₄, filtered and concentrated in vacuo. Benzyl (2,2-dimethoxyethyl)carbamate **5c** was obtained without further purification as a colorless liquid (3.19 g, 89%). Analytical data is in accordance with the literature.^[3]

R_f (*n*-hexane:EtOAc = 7:3) 0.27.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.42 – 7.27 (m, 5H), 5.10 (s, 2H), 4.96 (s, 1H), 4.38 (t, J=5.4 Hz, 1H), 3.39 (s, 6H), 3.34 (t, J=5.7 Hz, 2H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 156.5, 136.5, 128.7, 128.3, 128.3, 102.9, 67.0, 54.5, 42.6.

MS (ESI) m/z calcd for C₁₂H₁₇NO₄Na⁺ 262.1 [M+Na]⁺, found 261.9 [M+Na]⁺. HRMS (EI) m/z calcd for C₁₂H₁₇NO₄ 239.1158 [M]⁺, found 239.1149 [M]⁺. IR (v in cm⁻¹): 3342 (w), 2940 (w), 2834 (w), 1705 (s), 1522 (s), 1455 (m), 1366 (w), 1244 (s), 1128 (s), 1061 (s), 966 (m), 736 (m), 696 (s), 547 (w).

2.1.4 (9H-fluoren-9-yl)methyl (2,2-dimethoxyethyl)carbamate 5d



Prepared according to literature.^[3]

To a solution of 2,2-dimethoxyethylamine (1.6 mL, 15.0 mmol) in Et₂O (75 mL) was added K₂CO₃ (6.20 g, 44.9 mmol) and water (75 mL). The reaction mixture was cooled to 0 °C and 9-fluorenylmethyl chloroformate (3.88 g, 15.0 mmol) was added in one portion. The reaction mixture was allowed to warm to rt and stirred for 16 h. The two layers were separated and the aqueous layer was extracted with Et₂O (2 × 50 mL). The combined organic layers were washed with 5% aqueous citric acid (3 × 80 mL) and brine (2 × 80 mL), dried over Na₂SO₄, filtered and concentrated in vacuo. (9*H*-fluoren-9-yl)methyl (2,2-dimethoxyethyl)carbamate **5d** was obtained without further purification as a colorless solid (4.59 g, 93%). Analytical data is in accordance with the literature.^[4]

R_f (*n*-hexane:EtOAc = 4:1) 0.14.

m.p. 100-102 °C

¹**H NMR** (400 MHz, CDCl₃) δ = 7.80 – 7.74 (m, 2H), 7.63 – 7.57 (m, 2H), 7.45 – 7.37 (m, 2H), 7.32 (td, J=7.4, 1.2, 2H), 5.00 (t, J=6.1, 1H), 4.59 – 4.35 (m, 3H), 4.23 (t, J=7.0, 1H), 3.41 (s, 5H), 3.35 (t, J=5.7, 3H).

¹³C NMR (101 MHz, CDCl₃) δ = 156.6, 144.0, 141.4, 127.8, 127.2, 125.2, 120.1, 103.0, 66.9, 54.6, 47.4, 42.7.

MS (ESI) m/z calcd for $C_{19}H_{21}NO_4Na^+$ 350.1 [M+Na]⁺, found 350.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{19}H_{21}NO_4$ 327.1471 [M]⁺, found 327.1455 [M]⁺.

IR (v in cm⁻¹): 3333 (w), 2945 (w), 2836 (w), 1697 (s), 1534 (s), 1447 (w), 1332 (w), 1271 (s), 1199 (w), 1149 (w), 1132 (m), 1108 (s), 1049 (s), 998 (s), 966 (m), 918 (w), 758 (s), 732 (s), 620 (m). 536 (m).

2.1.5 N-(2,2-Dimethoxyethyl)-4-methylbenzamide 5e



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and 4-methylbenzoyl chloride (2.93 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = $95:5 \rightarrow 40:60$) afforded *N*-(2,2-dimethoxyethyl)-3-methylbenzamide **5e** as a colorless solid (4.20 g, 94%).

R_f (*n*-hexane:EtOAc = 1:1) 0.47.

m.p. 62-63 °C

¹**H NMR** (400 MHz, CDCl₃) δ 7.75 – 7.54 (m, 2H), 7.25 – 7.20 (m, 2H), 6.31 (s, 1H), 4.48 (t, J = 5.3 Hz, 1H), 3.60 (t, J = 5.6 Hz, 2H), 3.43 (s, 6H), 2.39 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 167.6, 142.1, 131.6, 129.4, 127.1, 103.0, 54.8, 54.7, 41.6, 21.6.

MS (ESI) m/z calcd for $C_{12}H_{17}NO_3Na^+$ 246.1 [M+Na]⁺, found 246.1 [M+Na]⁺.

HRMS (EI) m/z calcd for C₁₂H₁₇NO₃ 223.1208 [M]⁺, found 223.1212 [M]⁺.

IR (v in cm⁻¹): 3270 (w), 2945 (w), 2831 (w), 1630 (m), 1550 (s), 1507 (s), 1371 (w), 1336 (m), 1304 (m), 1195 (m), 1111 (s), 1062 (s), 1040 (m), 979 (w), 844 (m), 714 (w), 664 (s).

2.1.6 N-(2,2-Dimethoxyethyl)-4-methoxybenzamide 5f



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and 4-methoxybenzoyl chloride (2.98 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)-4-methoxybenzamide **5f** as a colorless solid (4.15 g, 87%).

 \mathbf{R}_{f} (*n*-hexane:EtOAc = 1:1) 0.20.

m.p. 106-107 °C

¹**H NMR** (400 MHz, CDCl₃) δ 7.74 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 6.25 (s, 1H), 4.48 (t, J = 5.3 Hz, 1H), 3.85 (s, 3H), 3.59 (t, J = 5.6 Hz, 2H), 3.43 (s, 6H).

¹³**C NMR** (101 MHz, CDCl₃) δ 167.1, 162.3, 128.9, 126.6, 113.8, 113.8, 103.0, 55.4, 54.7, 54.6, 41.5.

MS (ESI) m/z calcd for $C_{12}H_{17}NO_4Na^+$ 262.1 [M+Na]⁺, found 262.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{12}H_{17}NO_4$ 239.1158 [M]⁺, found 239.1161 [M]⁺.

IR (v in cm⁻¹): 3300 (w), 2983 (w), 2836 (w), 1632 (m), 1607 (w), 1540 (m), 1503 (m), 1457 (w), 1302 (m), 1251 (s), 1204 (w), 1184 (m), 1097 (w), 1068 (s), 970 (m), 845 (m) 685 (w).

2.1.7 4-Bromo-*N*-(2,2-dimethoxyethyl)benzamide 5g



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and 4-bromobenzoyl chloride (4.83 g, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded 4-bromo-*N*-(2,2-dimethoxyethyl)benzamide **5g** as a colorless solid (4.66 g, 81%).

R_f (*n*-hexane:EtOAc = 1:1) 0.43.

m.p. 72-73 °C

¹**H NMR** (400 MHz, CDCl₃) δ = 7.67 – 7.62 (m, 2H), 7.60 – 7.55 (m, 2H), 6.29 (s, 1H), 4.48 (t, J=5.2 Hz, 1H), 3.65 - 3.56 (m, 2H), 3.44 (s, 6H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl_3) δ 166.7, 133.2, 131.9, 131.9, 128.7, 126.4, 54.8, 54.7, 41.7.

MS (ESI) m/z calcd for $C_{11}H_{14}BrNO_{3}Na^{+} 310.0 [M+Na]^{+}$, found 310.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{11}H_{14}BrNO_3 239.1158 \text{ [M]}^+$, found 239.1161 [M]⁺.

IR (v in cm⁻¹): 3253 (w), 2942 (w), 1630 (m), 1589 (m), 1551 (s), 1485 (m), 13887 (w), 1304 (w), 1191 (w), 1096 (m), 1058 (s), 1039 (s), 1008 (m), 917 (m), 852 (s), 752 (w), 669 (s).

2.1.8 *N*-(2,2-Dimethoxyethyl)-4-(trifluoromethyl)benzamide **5h**



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and 4-(trifluoromethyl)benzoyl chloride (3.28 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)-4-(trifluoromethyl)-benzamide **5h** as a colorless solid (4.75 g, 86%).

R_f (*n*-hexane:EtOAc = 1:1) 0.40.

m.p. 62-64 °C

¹**H NMR** (400 MHz, CDCl₃) δ 7.92 − 7.84 (m, 2H), 7.74 − 7.64 (m, 2H), 6.40 (s, 1H), 4.50 (t, J = 5.1 Hz, 1H), 3.62 (t, J = 5.4 Hz, 2H), 3.44 (s, 6H).

¹³**C NMR** (101 MHz, CDCl₃) δ 166.4, 137.7, 133.4 (q, J = 32.7 Hz), 127.6, 125.7(q, J = 3.8 Hz), 125.1, 122.4, 119.7, 102.6, 54.8, 54.8, 41.7.

¹⁹**F {1H} NMR** (376 MHz, CDCl₃) δ -63.0.

MS (ESI) m/z calcd for $C_{12}H_{14}F_3NO_3Na^+$ 300.1 [M+Na]⁺, found 300.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{12}H_{13}$ F₃NO₃ 276.0853 [M-H]⁻, found 276.0852 [M-H]⁻.

IR (v in cm⁻¹): 3288 (w), 2942 (w), 1637 (m), 1553 (m), 1429 (w), 1326 (s), 1309 (m), 1205 (w), 1159 (m), 1109 (s), 1064 (s), 1012 (m), 973 (w), 856 (m), 685 (m).

2.1.9 N-(2,2-Dimethoxyethyl)-4-nitrobenzamide 5i



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and 4-nitrobenzoyl chloride (4.83 g, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)-4-nitrobenzamide **5i** as a yellow solid (4.52 g, 89%).

R_f (*n*-hexane:EtOAc = 1:1) 0.27.

m.p. 81-82 °C

¹**H NMR** (400 MHz, CDCl₃) δ 8.27 (d, J = 8.8 Hz, 2H), 7.93 (d, J = 8.8 Hz, 2H), 6.52 (s, 1H), 4.49 (t, J = 5.0 Hz, 1H), 3.62 (dd, J = 5.7, 5.1 Hz, 2H), 3.43 (s, 6H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl₃) δ 165.7, 149.7, 140.0, 123.9, 123.9, 102.6, 102.5, 54.9, 54.8, 41.8.

MS (ESI) m/z calcd for $C_{11}H_{14}N_2O_5Na^+$ 253.1 [M+Na]⁺, found 253.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{11}H_{14}N_2O_5 254.0903 \text{ [M]}^+$, found 254.0891 [M]⁺.

IR (v in cm⁻¹): 3335 (w), 2944 (w), 1637 (m), 1599 (m), 1543 (m), 1523 (m), 1419 (w), 1340 (s), 1290 (s), 1203 (m), 1122 (m), 1058 (s), 947 (m), 851 (m). 717 (m).

2.1.10 N-(2,2-Dimethoxyethyl)-2-methylbenzamide 5j



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and 2-methylbenzoyl chloride (3.33 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)-2-methylbenzamide **5j** as a colorless solid (4.07 g, 91%).

 R_{f} (*n*-hexane:EtOAc = 1:1) 0.40.

m.p. 58-59 °C

¹**H NMR** (400 MHz, CDCl₃) δ 7.39 − 7.28 (m, 2H), 7.25 − 7.16 (m, 2H), 5.96 (s, 1H), 4.50 (t, J = 5.3 Hz, 1H), 3.59 (t, J = 5.6 Hz, 2H), 3.43 (s, 6H), 2.45 (s, 3H).

 $^{13}\textbf{C}$ NMR (101 MHz, CDCl_3) δ 170.3, 136.4, 136.1 131.1, 130.0, 126.9, 125.8, 102.8, 54.6, 54.5, 41.3, 19.9.

MS (ESI) m/z calcd for $C_{12}H_{17}NO_3Na^+$ 246.1 [M+Na]⁺, found 246.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{12}H_{17}NO_3$ 223.1208 [M]⁺, found 223.1214 [M]⁺.

IR (v in cm⁻¹): 3288 (w), 2941 (w), 1636 (s), 1600 (w), 1536 (s), 1369 (w), 1288 (w), 1205 (w), 1096 (w), 1066 (s), 1037 (m), 970 (m), 853 (w), 720 (s), 688 (s).

2.1.11 N-(2,2-Dimethoxyethyl)-2-iodobenzamide 5k



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and 2-iodobenzoyl chloride (4.65 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)-2-iodobenzamide **5k** as a colorless solid (5.33 g, 79%).

R_f (*n*-hexane:EtOAc = 1:1) 0.30.

m.p. 63-65 °C

¹H NMR (400 MHz, CDCl₃) 7.93 – 7.78 (m, 1H), 7.46 – 7.32 (m, 2H), 7.10 (ddd, J = 7.9 Hz, 6.1 Hz, 3.1 Hz, 1H), 5.99 (s, 1H), 4.54 (t, J = 5.4 Hz, 1H), 3.60 (t, J = 5.6 Hz, 2H), 3.44 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 169.6, 142.2, 140.0, 131.3, 128.4, 128.3, 102.5, 92.5, 54.6, 41.5. MS (ESI) m/z calcd for C₁₁H₁₄INO₃Na⁺ 358.0 [M+Na]⁺, found 358.1 [M+Na]⁺. HRMS (EI) m/z calcd for C₁₁H₁₄INO₃ 335.0018 [M]⁺, found 335.0026 [M]⁺. IR (v in cm⁻¹): 3267 (w), 2935 (w), 1641 (s), 1534 (s), 1458 (w), 1420 (w), 1309 (m), 1191 (w), 1134 (m), 1095 (w), 1066 (s), 1034 (m), 967 (s), 808 (w), 680 (s).

2.1.12 N-(2,2-Dimethoxyethyl)-3-methylbenzamide 5l



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and 3-methylbenzoyl chloride (2.91 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)-3-methylbenzamide **5I** as a colorless solid (4.15 g, 93%).

 R_{f} (*n*-hexane:EtOAc = 1:1) 0.33.

m.p. 48-49 °C

¹**H NMR** (400 MHz, CDCl₃) δ 7.60 (s, 1H), 7.57 – 7.48 (m, 1H), 7.36 – 7.29 (m, 2H), 6.33 (bs, 1H), 4.49 (t, J = 5.3 Hz, 1H), 3.60 (t, J = 5.5 Hz, 2H), 3.43 (s, 3H), 2.39 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 167.9, 138.6, 134.4, 132.4, 128.6, 127.9, 127.8, 124.0, 102.9, 54.8, 41.6, 21.5.

MS (ESI) m/z calcd for $C_{12}H_{17}NO_3Na^+$ 246.1 [M+Na]⁺, found 246.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{12}H_{17}NO_3$ 223.1208 [M]⁺, found 223.1218 [M]⁺.

IR (v in cm⁻¹):3297 (w), 2938 (w), 1639 (s), 1587 (w), 1536 (s), 1458 (w). 1313 (m), 1208 (m), 1131 (m), 1100 (m), 1067 (s), 1036 (m), 974 (m), 815 (w), 698 (s).

2.1.13 N-(2,2-Dimethoxyethyl)furan-2-carboxamide 5m



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and furan-2-carbonyl chloride (2.18 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)furan-2-carboxamide **5m** as a colorless solid (3.80 g, 95%).

 R_{f} (*n*-hexane:EtOAc = 7:3) 0.30.

m.p. 89-90 °C

¹**H NMR** (400 MHz, CDCl₃) δ 7.48 – 7.38 (m, 1H), 7.18 – 7.08 (m, 1H), 6.53 (s, 1H), 6.49 (dd, J = 3.5, 1.7 Hz, 1H), 4.46 (t, J = 5.3 Hz, 1H), 3.62 – 3.53 (m, 2H), 3.43 (s, 5H).

¹³**C NMR** (101 MHz, CDCl₃) δ 158.5, 147.9, 144.1, 114.5, 112.2, 102.8, 54.6, 54.6, 40.6.

MS (ESI) m/z calcd for $C_9H_{13}NO_4Na^+ 222.1 [M+Na]^+$, found 222.1 [M+Na]⁺.

HRMS (EI) m/z calcd for C₉H₁₃NO₄ 199.0845 [M]⁺, found 199.0842 [M]⁺.

IR (v in cm⁻¹): 3253 (w), 2950 (w), 1637 (m), 1591 (s), 1527 (s), 1472 (m), 1368 (w), 1309 (m), 1189 (s), 1133 (s), 1065 (s), 1010 (m), 968 (m), 863 (w), 768 (m), 695 (m).

2.1.14 N-(2,2-Dimethoxyethyl)cyclohexanecarboxamide 5n



Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and cyclohexanecarbonyl chloride (3.02 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)cyclohexane-carboxamide **5n** as a colorless solid (3.96 g, 92%).

R_f (*n*-hexane:EtOAc = 1:1) 0.33.

m.p. 70-71 °C

¹**H NMR** (400 MHz, CDCl₃) δ 5.63 (s, 1H), 4.36 (t, J = 5.3 Hz, 1H), 3.39 (s, 6H), 3.43 – 3.34 (m, 2H), 2.08 (tt, J = 11.7, 3.5 Hz, 1H), 1.89 – 1.74 (m, 4H), 1.72 – 1.61 (m, 1H), 1.54 – 1.36 (m, 2H), 1.33 – 1.17 (m, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 176.4, 102.9, 54.6, 54.6, 45.6, 40.9, 29.7, 25.8.

MS (ESI) m/z calcd for $C_{11}H_{21}NO_3Na^+ 238.1 [M+Na]^+$, found 338.2 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{11}H_{21}NO_3$ 215.1521 [M]⁺, found 215.1531 [M]⁺.

IR (v in cm⁻¹): 3281 (m), 2928 (m), 2852 (w), 1645 (s), 1558 (s), 1144 (w), 1321 (w), 1257 (w), 1189 (s), 1133 (s), 1099 (s), 1060 (s), 971 (s), 858 (w), 705 (m).





Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and acetyl chloride (1.56 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)acetamide **50** as a yellow oil (1.61 g, 55%).

 R_{f} (*n*-hexane:EtOAc = 1:1) 0.15.

¹H NMR (400 MHz, CDCl₃) δ = 5.70 (s, 1H), 4.37 (t, J=5.2, 1H), 3.46 – 3.36 (m, 8H), 1.99 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 170.5, 102.7, 54.5, 41.1, 23.3.

MS (ESI) m/z calcd for $C_6H_{14}NO_3$ 148.1 [M+H]⁺, found 148.0 [M+H]⁺.

HRMS (EI) m/z calcd for $C_6H_{13}NO_3$ 147.0895 [M]⁺, found 147.0887 [M]⁺.

IR (v in cm⁻¹): 3299 (w), 2939 (w), 2834 (w), 1738 (w), 1652 (s), 1545 (s), 1435 (m), 1372 (m), 1285 (w), 1194 (m), 1128 (s), 1096 (s), 1058 (s), 971 (w), 923 (w), 818 (w), 600 (m).

2.1.16 *N*-(2,2-Dimethoxyethyl)butyramide **5p**



5p

Prepared according to **GP1** from 2,2-dimethoxyethanamine (2.20 mL, 20.0 mmol, 1.0 equiv), Et₃N (8.34 mL, 60.0 mmol, 3.0 equiv) and butanoyl chloride (2.30 mL, 22.0 mmol, 1.1 equiv) in CH₂Cl₂ (30 mL). Purification by flash chromatography via puriflash XS 420+ purifier machine, HP_30µm_F0040 flash column (*n*-hexane:EtOAc = 95:5 \rightarrow 40:60) afforded *N*-(2,2-dimethoxyethyl)butyramide **5p** as a colorless oil (2.72 g, 78%).

R_f (*n*-hexane:EtOAc = 1:1) 0.30.

¹**H NMR** (400 MHz, CDCl₃) δ = 5.71 (s, 1H), 4.35 (t, J=5.3 Hz, 1H), 3.51 - 3.28 (m, 8H), 2.19 - 2.08 (m, 2H), 1.71 - 1.56 (m, 2H), 0.92 (t, J=7.4 Hz, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 173.3, 102.8, 54.5, 40.9, 38.7, 19.2, 13.8.

MS (ESI) m/z calcd for $C_8H_{17}NO_3Na^+$ 198.1 [M+Na]⁺, found 198.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{11}H_{21}NO_3$ 175.1208 [M]⁺, found 175.1201 [M]⁺.

IR (v in cm⁻¹): 3300 (w), 2962 (w), 2834 (w), 1646 (s), 1542 (s), 1459 (m), 1369 (w), 1276 (w), 1196 (m), 1128 (s), 1099 (s), 1056 (s), 973 (m), 929 (w), 823 (w), 709 (w).

2.2 Aldehydes

GENEREAL PROCEDURE 2 (TP2)



Aldehydes were prepared according to modified procedure.^[5]

Acetale **5** (1.0 equiv) was dissolved in THF (4 mL/mmol) and cooled to 0 °C. HCl (4 mL/mmol, 6 M in water) was slowly added. The ice bath was removed and the reaction was stirred for 30 min at room temperature. After TLC analysis showed complete consumption of the acetale, sat. aq. NaCl solution (15 mL) was added and diluted with CH_2Cl_2 (30 mL). The organic layer was separated and the aqueous phase was extracted with CH_2Cl_2 (2x 30 mL). The combined organic extracts were dried over Na_2SO_4 . (Note! The crude aldehydes of type **3** are unstable towards prolonged contact with water. Therefore, a rapid workup is recommended). After evaporation of the solvents the crude product is dried at room temperature over 2-3 h under oil pump vacuum (10^{-2} mbar). Crude aldehydes **3** were only characterized briefly via ¹H-NMR and used without further purification for the synthesis of the 2-oxyenamides.

2.2.1 N-(2-Oxoethyl)benzamide 3a



Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)benzamide **5a** (1.01g, 6.1 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3a** as a colorless solid (990 mg, 99%). Analytical data are in accordance with the literature.^[5]

R_f (*n*-hexane:EtOAc = 3:7) 0.32.

¹**H NMR** (400 MHz, CDCl₃) δ 9.72 (s, 1H), 7.81 (d, J = 7.4 Hz, 1H), 7.51 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 4.36 (d, J = 4.8 Hz, 1H).

2.2.2 Benzyl (2-oxoethyl)carbamate **3c**



Prepared according to GP2 from benzyl (2,2-dimethoxyethyl)carbamate **5c** (1.20 g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3c** as a colorless oil (561 mg, 58%).

R_f (*n*-hexane:EtOAc = 1:1) 0.38.

¹**H NMR** (400 MHz, CDCl₃) δ 9.66 (s, 1H), 7.39 – 7.32 (m, 5H), 5.43 (s, 1H), 5.13 (s, 2H), 4.16 (d, J = 5.1 Hz, 2H).

2.2.3 (9H-fluoren-9-yl)methyl (2-oxoethyl)carbamate 3d

Prepared according to GP2 from (9*H*-fluoren-9-yl)methyl (2,2-dimethoxyethyl)carbamate **5d** (1.64 g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3d** as a colorless solid (1.39 mg, 99%).

R_f (*n*-hexane:EtOAc = 1:1) 0.35.

¹**H NMR** (400 MHz, CDCl₃) δ 9.67 (s, 1H), 7.83 – 7.74 (m, 2H), 7.60 (d, J = 7.5 Hz, 2H), 7.46 – 7.37 (m, 2H), 7.31 (dd, J = 7.5, 1.2 Hz, 2H), 5.44 (s, 1H), 4.43 (d, J = 7.0 Hz, 2H), 4.24 (t, J = 6.9 Hz, 1H), 4.17 (d, J = 5.1 Hz, 2H).

2.2.4 4-Methyl-N-(2-oxoethyl)benzamide 3e



Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)-3-methylbenzamide **5e** (1.12 g, 5.0 mmol, 1.0 equiv) and 6 M HCl (17 mL) in THF (17 mL). Removal of the solvents afforded the crude aldehyde **3e** as a colorless solid (813 mg, 92%).

R_f (*n*-hexane:EtOAc = 3:7) 0.41.

¹**H NMR** (400 MHz, CDCl₃) δ 9.74 (s, 1H), 7.72 (d, *J* = 8.3 Hz, 2H), 7.25 (d, *J* = 8.1 Hz, 2H), 4.40 (d, *J* = 4.7 Hz, 2H), 2.40 (s, 3H).

2.2.5 4-Methoxy-N-(2-oxoethyl)benzamide 3f



Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)-4-methoxybenzamide **5f** (1.20g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3f** as a colorless solid (460 mg, 48%).

R_f (*n*-hexane:EtOAc = 3:7) 0.27.

¹**H NMR** (400 MHz, CDCl₃) δ 9.76 (s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 6.83 (s, 1H), 4.40 (d, J = 4.7 Hz, 2H), 3.85 (s, 3H).

2.2.6 4-Bromo-N-(2-oxoethyl)benzamide 3g



Prepared according to GP2 from 4-bromo-*N*-(2,2-dimethoxyethyl)benzamide **5g** (1.44 g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3g** as a colorless solid (1.19 g, 98%).

R_f (*n*-hexane:EtOAc = 3:7) 0.34.

¹**H NMR** (400 MHz, CDCl₃) δ 9.77 (s, 1H), 7.73 – 7.67 (m, 2H), 7.63 – 7.56 (m, 2H), 6.89 (s, 1H), 4.42 (d, J = 4.7 Hz, 2H).

2.2.7 *N*-(2-Oxoethyl)-4-(trifluoromethyl)benzamide **3h**



Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)-4-(trifluoromethyl)benzamide **5h** (1.39 g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3h** as a colorless solid (1.07 mg, 93%).

R_f (*n*-hexane:EtOAc = 3:7) 0.33.

¹**H NMR** (400 MHz, CDCl₃) δ 9.79 (s, 1H), 7.93 (d, J = 8.1 Hz, 2H), 7.73 (d, J = 8.2 Hz, 2H), 6.94 (s, 1H), 4.46 (d, J = 4.6 Hz, 2H).

2.2.8 4-Nitro-N-(2-oxoethyl)benzamide 3i



Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)-4-nitrobenzamide **5i** (1.27 g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3i** as a colorless solid (770 mg, 74%).

 R_{f} (*n*-hexane:EtOAc = 3:7) 0.20.

¹**H NMR** (400 MHz, CDCl₃) δ 9.80 (s, 1H), 8.36 – 8.21 (m, 2H), 8.08 – 7.94 (m, 2H), 6.99 (s, 1H), 4.48 (d, J = 4.6 Hz, 2H).

2.2.9 2-Methyl-N-(2-oxoethyl)benzamide 3j



3j

Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)-2-methylbenzamide **5j** (1.12g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3j** as a colorless solid (720 mg, 81%).

R_f (*n*-hexane:EtOAc = 3:7) 0.40.

¹**H NMR** (400 MHz, CDCl₃) δ 9.72 (s, 1H), 7.44 – 7.39 (m, 1H), 7.36 – 7.30 (m, 1H), 7.25 – 7.18 (m, 2H), 6.60 (s, 1H), 4.36 (d, *J* = 5.0 Hz, 2H), 2.44 (s, 3H).

2.2.10 2-lodo-N-(2-oxoethyl)benzamide 3k



Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)-2-iodobenzamide **5k** (838 mg, 2.5 mmol, 1.0 equiv) and 6 M HCl (9 mL) in THF (9 mL). Removal of the solvents afforded the crude aldehyde **3k** as a yellow solid (700 mg, 97%).

R_f (*n*-hexane:EtOAc = 3:7) 0.33.

¹**H NMR** (400 MHz, CDCl₃) δ 9.79 (s, 1H), 7.94 – 7.84 (m, 1H), 7.48 – 7.36 (m, 2H), 7.18 – 7.10 (m, 1H), 6.55 (s, 1H), 4.44 (d, *J* = 4.8 Hz, 2H).

2.2.11 3-Methyl-N-(2-oxoethyl)benzamide 31



31

Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)-3-methylbenzamide **5I** (1.12g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3I** as a colorless oil (720 mg, 81%).

R_f (*n*-hexane:EtOAc = 3:7) 0.40.

¹**H NMR** (400 MHz, CDCl₃) δ 9.76 (s, 1H), 7.71 – 7.54 (m, 2H), 7.43 – 7.28 (m, 2H), 6.94 (s, 1H), 4.41 (d, *J* = 4.7 Hz, 2H), 2.40 (s, 3H).

2.2.12 N-(2-Oxoethyl)furan-2-carboxamide 3m



Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)furan-2-carboxamide **5m** (996 mg, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3m** as a colorless solid (393 mg, 51%).

 R_{f} (*n*-hexane:EtOAc = 3:7) 0.28.

¹**H NMR** (400 MHz, CDCl₃) δ 9.75 (s, 1H), 7.55 – 7.41 (m, 1H), 7.22 – 7.09 (m, 1H), 7.02 (s, 1H), 6.52 (dd, J = 3.5, 1.8 Hz, 1H), 4.39 (d, J = 5.0 Hz, 2H).

2.2.13 N-(2-Oxoethyl)cyclohexanecarboxamide 3n



3n

Prepared according to GP2 from *N*-(2,2-dimethoxyethyl)cyclohexanecarboxamide **5n** (1.08 g, 5.0 mmol, 1.0 equiv) and 6 M HCl (18 mL) in THF (18 mL). Removal of the solvents afforded the crude aldehyde **3n** as a colorless solid (747 mg, 88%).

R_f (*n*-hexane:EtOAc = 3:7) 0.25.

¹**H NMR** (400 MHz, CDCl₃) δ 9.68 (s, 1H), 6.18 (s, 1H), 4.22 (d, *J* = 4.8 Hz, 2H), 2.18 (tt, *J* = 11.7, 3.5 Hz, 1H), 1.93 – 1.85 (m, 2H), 1.84 – 1.77 (m, 2H), 1.72 – 1.64 (m, 1H), 1.51 – 1.38 (m, 2H), 1.36 – 1.14 (m, 3H).

2.3 (*Z*)-Oxyenamides/(*Z*)-oxyencarbamates GENERAL PROCEDURE 3 (GP3)



Prepared according to our previously reported procedure.^[6]

To a stirred solution of triethylamine (1.7 equiv) and the corresponding acyl chloride (1.3 equiv) in dichlormethane (2 mL/mmol) was added dropwise a solution of the aldehyde **3** (1.0 equiv) in dichlormethane (2 mL/mmol) over 5 min. The reaction mixture was stirred for 1 h at room temperature. After TLC analysis showed complete consumption of the aldehyde, saturated NaHCO₃ solution was added (20 mL). The organic layers were separated and the aqueous phase was extracted with dichlormethane (2x 30 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by flash chromatography afforded the desired (*Z*)-oxyenamide/(*Z*)-oxyencarbamate **1/2** as analytically pure product. All oxyenamides of type **1/2** tend to decompose upon contact to any type of acid. Therefore, column chromotography was performed with 0.2 vol% NEt₃ as additive. CDCl₃ for NMR spectroscopy was passed through a short plug of basic alumina before use.

2.3.1 (Z)-2-Benzamidovinyl benzoate 1a



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (774 mg, 4.74 mmol, 1.0 equiv), triethylamine (1.1 mL, 8.06 mmol, 1.7 equiv) and benzoyl chloride (0.72 mL, 6.16 mmol, 1.3 equiv) in a total of 20 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl benzoate **1a** (927 mg, 73%) as colorless solid. Analytical data are in accordance with those previously reported.^[6] **R**_f (*n*-hexane:EtOAc = 4:1) 0.38.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.17 – 8.06 (m, 2H), 7.97 (d, J=10.2 Hz, 1H), 7.91 – 7.81 (m, 2H), 7.68 – 7.62 (m, 1H), 7.61 – 7.56 (m, 1H), 7.55 – 7.48 (m, 4H), 7.11 (d, J=5.1 Hz, 1H), 6.86 (dd, J=10.7 Hz, 5.1 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 164.0, 162.7, 134.0, 133.4, 132.4, 130.0, 129.0, 128.9, 128.8, 127.3, 121.9, 109.5.

IR (ATR, v in cm⁻¹): 3275 (w), 3110 (w), 3032 (w), 1723 (m), 1686 (w), 1643 (m), 1601 (w), 1580 (w),

1519 (s), 1484 (s), 1451 (w), 1249 (s), 1146 (m), 1113 (s), 1093 (s), 1068 (s), 798 (w), 687 (s).

MS (ESI) m/z calcd for $C_{16}H_{13}NO_3Na 290.1 [M+Na]^+$, found 290.2 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{16}H_{13}NO_3$ 267.0895 [M]⁺, found 267.0901 [M]⁺.

2.3.2 (Z)-2-(((Benzyloxy)carbonyl)amino)vinyl benzoate 1c

Prepared according to **GP3** from benzyl (2-oxoethyl)carbamate **3c** (561 mg, 4.59 mmol, 1.0 equiv), triethylamine (0.69 mL, 4.93 mmol, 1.7 equiv) and benzoyl chloride (0.43 mL, 3.77 mmol, 1.3 equiv) in a total of 12 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(((benzyloxy)carbonyl)amino)vinyl benzoate **1c** (505 mg, 59%) as colorless solid. Analytical data are in accordance with those previously reported.^[6]

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.47.

m.p. 69-71 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.07 (d, J = 7.7 Hz, 2H), 7.62 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 7.42 – 7.33 (m, 5H), 6.95 (d, J = 5.1 Hz, 1H), 6.67 (d, J = 11.3 Hz, 1H), 6.38 (dd, J = 11.0, 5.1 Hz, 1H), 5.20 (s, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 162.8, 153.1, 135.7, 133.8, 130.0, 128.8, 128.7, 128.7, 128.6, 119.9, 110.5, 67.8.

IR (ATR, v in cm⁻¹): 3270 (w), 3128 (w), 3030 (w), 1729 (s), 1689 (s), 1601 (w), 1518 (s), 1450 (m), 1360 (w), 1228 (s), 1159 (m), 1100 (s), 1074 (s), 1026 (m), 906 (w), 741 (m), 696 (s).

MS (ESI) m/z calcd for $C_{17}H_{15}NO_4Na$ 320.1 [M+Na]⁺, found 320.2 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{17}H_{25}NO_3$ 297.1001 [M]⁺, found 297.0997 [M]⁺.

2.3.3 (Z)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)vinyl benzoate 1d

Prepared according to **GP3** from (9*H*-fluoren-9-yl)methyl (2-oxoethyl)carbamate **3d** (1.39 mg, 4.95 mmol, 1.0 equiv), triethylamine (1.2 mL, 8.50 mmol, 1.7 equiv) and benzoyl chloride (0.75 mL, 6.5 mmol, 1.3 equiv) in a total of 18 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-((((9*H*-fluoren-9-yl)methoxy)-carbonyl)amino)vinyl benzoate **1d** (1.30 g, 67%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.41.

m.p. 140-142 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.14 – 8.07 (m, 2H), 7.80 (s, 2H), 7.62 (t, *J* = 7.4 Hz, 3H), 7.51 (d, *J* = 7.8 Hz, 2H), 7.45 – 7.41 (m, 2H), 7.34 (td, *J* = 7.4, 1.2 Hz, 2H), 6.95 (d, *J* = 5.1 Hz, 1H), 6.67 (d, *J* = 11.2 Hz, 1H), 6.38 (dd, *J* = 10.9, 5.1 Hz, 1H), 4.54 (d, *J* = 6.8 Hz, 2H), 4.29 (d, *J* = 6.9 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 162.9, 153.2, 143.7, 141.5, 133.9, 130.1, 128.8, 128.0, 127.3, 125.1, 120.2, 120.1, 110.5, 67.7, 47.2.

IR (ATR, v in cm⁻¹): 327 (w), 3063 (w), 1738 (m), 1717 (s), 1472 (w), 1448 (m), 1398 (m), 1314 (s), 1264 (s), 1161 (m), 1103 (s), 1031 (m), 941 (w), 763 (m), 739 (s), 705 (s), 699 (s), 593 (m), 5542 (m).

MS (ESI) m/z calcd for $C_{24}H_{19}NO_4Na 408.1 [M+Na]^+$, found 408.0 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{24}H_{19}NO_4$ 385.1314 [M]⁺, found 385.1299 [M]⁺.

2.3.4 (Z)-2-(4-Methylbenzamido)vinyl benzoate 1e



Prepared according to **GP3** from 4-methyl-*N*-(2-oxoethyl)benzamide **3e** (813 mg, 4.59 mmol, 1.0 equiv), triethylamine (1.08 mL, 7.80 mmol, 1.7 equiv) and benzoyl chloride (0.69 mL, 5.97 mmol, 1.3 equiv) in a total of 18 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(4-methylbenzamido)vinyl benzoate **1e** (890 mg, 69%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.39.

m.p. 161-162 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.16 – 8.01 (m, 2H), 7.79 (d, J=7.6 Hz, 2H), 7.63 (dd, J=15.6 Hz, 7.6 Hz, 3H), 7.52 (t, J=7.7 Hz, 2H), 7.43 (t, J=7.4 Hz, 2H), 7.34 (td, J=7.4 Hz, 1.2, 2H), 6.94 (d, J=5.2 Hz, 1H), 6.64 (d, J=11.0 Hz, 1H), 6.44 – 6.18 (m, 1H), 4.54 (d, J=6.7 Hz, 2H), 4.29 (t, J=6.8 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ = 162.9, 153.2, 143.6, 141.5, 133.9, 130.1, 128.8, 128.0, 127.3, 125.0, 120.2, 120.0, 110.5, 67.6, 47.1.

IR (ATR, v in cm⁻¹): 3248 (w), 3120 (w), 2359 (w), 1725 (s). 1695 (w), 1632 (s), 1524 (s), 1495 (s), 1450 (m), 1251 (s), 1183 (m), 1150 (s), 1090 (s), 1068 (s), 646 (w), 835 (m), 706 (s).
MS (ESI) m/z calcd for C₁₇H₁₅NO₃Na 304.1 [M+Na]⁺, found 304.3 [M+Na]⁺.
HRMS (EI) m/z calcd for C₁₇H₁₅NO₃ 281.1052 [M]⁺, found 281.1049 [M]⁺.

2.3.5 (Z)-2-(4-Methoxybenzamido)vinyl benzoate 1f



Prepared according to GP3 from 4-methoxy-N-(2-oxoethyl)benzamide 3f (460 mg, 2.38 mmol, 1.0 equiv), triethylamine (0.56 mL, 4.05 mmol, 1.7 equiv) and benzoyl chloride (0.36 mL, 3.09 mmol, 1.3 equiv) in a total of 5 mL dichlormethane. Purification by column chromatography (n-hexane:EtOAc + 0.2 vol% NEt3 = $19:1 \rightarrow 9:1$) afforded (Z)-2-(4-methoxybenzamido)vinyl benzoate 1f (550 mg, 78%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.33.

m.p. 144-146 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.13 – 8.06 (m, 2H), 7.94 (d, J=10.7 Hz, 1H), 7.85 – 7.78 (m, 2H), 7.68 – 7.59 (m, 1H), 7.51 (t, J=7.7 Hz, 2H), 7.06 (d, J=5.1 Hz, 1H), 7.00 – 6.93 (m, 2H), 6.83 (dd, J=10.6, 5.1 Hz, 1H), 3.86 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 163.4, 162.9, 162.7, 133.9, 130.0, 129.2, 128.9, 125.5, 121.4, 114.2, 109.7, 55.6.

IR (ATR, v in cm⁻¹): 3272 (w), 2935 (w), 2361 (w), 1722 s), 1695 (w), 1630 (s), 1602 (s), 1527 (m), 1494 (s), 1310 (m), 1248 (s), 1172 (s), 1150 (m), 1113 (s), 1092 (s), 1026 (s), 842 (s), 755 (m), 707 (s).

MS (ESI) m/z calcd for $C_{17}H_{15}NO_4Na$ 320.1 [M+Na]⁺, found 320.2 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{17}H_{15}NO_4$ 297.0001 [M]⁺, found 296.0988 [M]⁺.

2.3.6 (Z)-2-(4-Bromobenzamido)vinyl benzoate 1g



Prepared according to **GP3** from 4-bromo-*N*-(2-oxoethyl)benzamide **3g** (1.12 g, 4.63 mmol, 1.0 equiv), triethylamine (1.06 mL, 7.87 mmol, 1.7 equiv) and benzoyl chloride (0.70 mL, 6.02 mmol, 1.3 equiv) in

a total of 20 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl benzoate **1g** (1.21 g, 76%) as colorless solid. **R**_f (*n*-hexane:EtOAc = 4:1) 0.33.

m.p. 145-147 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.15 – 8.04 (m, 2H), 7.92 (d, J = 10.6 Hz, 1H), 7.75 – 7.69 (m, 2H), 7.69 – 7.60 (m, 3H), 7.57 – 7.47 (m, 2H), 7.10 (d, J = 5.1 Hz, 1H), 6.82 (dd, J = 10.6, 5.1 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 163.1, 162.7, 134.1, 132.3, 130.0, 128.9, 128.9, 128.7, 127.2, 122.2, 109.3.

IR (ATR, v in cm⁻¹): 3262 (w), 2922 (w), 2361 (w), 1722 (m), 1692 (m), 1634 (s), 1586 (m), 1519 (m), 1449 (w), 1301 (w), 1249 (s), 1151 (m), 1090 (s), 1067 (s), 1006 (m), 844 (m), 703 (s).

MS (ESI) m/z calcd for $C_{16}H_{11}BrNO_3$ 344.0 [M-H]⁻, found 344.1 [M-H]⁻.

HRMS (EI) m/z calcd for $C_{16}H_{12}BrNO_3$ 345.0001 [M]⁺, found 345.0001 [M]⁺.

2.3.7 (Z)-2-(4-(Trifluoromethyl)benzamido)vinyl benzoate **1h**



Prepared according to **GP3** from *N*-(2-oxoethyl)-4-(trifluoromethyl)benzamide **3h** (1.07 mg, 4.63 mmol, 1.0 equiv), triethylamine (1.09 mL, 7.87 mmol, 1.7 equiv) and benzoyl chloride (0.70 mL, 6.02 mmol, 1.3 equiv) in a total of 18 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(4-(trifluoromethyl)benzamido)vinyl benzoate **1h** (1.21 g, 78%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.36.

m.p. 136-138 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.15 – 8.07 (m, 2H), 8.00 – 7.92 (m, 3H), 7.77 (d, J=8.1 Hz, 2H), 7.70 – 7.62 (m, 1H), 7.53 (t, J=7.8 Hz, 2H), 7.14 (d, J=5.1 Hz, 1H), 6.85 (dd, J=10.6, 5.1 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 171.0, 162.8, 162.7, 136.7, 134.2, 133.9, 133.8, 130.3, 130.0, 129.0, 128.7, 128.6, 127.8, 126.1 (q, J=3.8), 122.3 (q, J=274), 109.2.

¹⁹**F {H} NMR** (376 MHz, CDCl₃) δ = -63.03.

IR (ATR, v in cm⁻¹): 3288 (w), 3012 (w), 2361 (w), 1730 (m), 1679 /w), 1647 (s), 1581 (w), 1522 (m), 1497 (m), 1407 (w), 1322 (s), 1261 (s), 1174 (m), 1119 (s), 1064 (s), 1012 (w), 859 (m), 702 (s).

MS (ESI) m/z calcd for $C_{17}H_{12}F_3NO_3Na 358.1 [M+Na]^+$, found 358.2 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{17}H_{12}F_3NO_3$ 335.0769 [M]⁺, found 335.0758 [M]⁺.

2.3.8 (Z)-2-(4-Nitrobenzamido)vinyl benzoate 1i



Prepared according to **GP3** from 4-nitro-*N*-(2-oxoethyl)benzamide **3i** (770 mg, 3.70 mmol, 1.0 equiv), triethylamine (0.87 mL, 6.25 mmol, 1.7 equiv) and benzoyl chloride (0.56 mL, 4.81 mmol, 1.3 equiv) in a total of 18 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(4-nitrobenzamido)vinyl benzoate **1i** (860 mg, 87%) as colorless solid. **R**_f (*n*-hexane:EtOAc = 4:1) 0.17.

m.p. 182-185 °C.

¹H NMR (400 MHz, CDCl₃) δ = 8.44 – 8.28 (m, 2H), 8.13 – 8.07 (m, 2H), 8.05 – 8.00 (m, 2H), 7.99 (s, 1H), 7.74 – 7.61 (m, 1H), 7.53 (t, J=7.8 Hz, 2H), 7.15 (d, J=5.1 Hz, 1H), 6.84 (dd, J=10.5, 5.1 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 162.6, 162.0, 150.1, 138.9, 134.3, 130.0, 128.6, 128.5, 124.3, 123.0, 109.0.

IR (ATR, v in cm⁻¹): 3269 (w), 3115 (w), 2360 (w), 1722 (m), 1688 (w), 1645 (m), 1601 (m), 1517 (s), 1452 (w), 1341 (m), 1245 (s), 1149 (m), 1116 (s), 1093 (s), 1068 (m), 843 (m), 702 (s).

MS (ESI) m/z calcd for $C_{16}H_{11}N_2O_5$ 311.1 [M-H]⁻, found 311.1 [M-H]⁻.

HRMS (EI) m/z calcd for $C_{16}H_{12}N_2O_5$ 312.0746 [M]⁺, found 312.0732 [M]⁺.

2.3.9 (Z)-2-(2-Methylbenzamido)vinyl benzoate 1j



Prepared according to **GP3** from 2-methyl-*N*-(2-oxoethyl)benzamide **3j** (719 mg, 4.06 mmol, 1.0 equiv), triethylamine (0.96 mL, 6.70 mmol, 1.7 equiv) and benzoyl chloride (0.61 mL, 5.27 mmol, 1.3 equiv) in a total of 18 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(2-methylbenzamido)vinyl benzoate **1j** (720 mg, 63%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.23.

m.p. 118-121 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.09 – 8.02 (m, 2H), 7.66 – 7.55 (m, 2H), 7.54 – 7.44 (m, 3H), 7.44 – 7.36 (m, 1H), 7.33 – 7.27 (m, 2H), 7.09 (d, J=5.1 Hz, 1H), 6.84 (dd, J=10.8, 5.1 Hz, 1H), 2.53 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 166.3, 162.7, 137.1, 134.9, 131.5, 130.8, 130.0, 128.8, 128.6, 127.0, 126.1, 121.6, 109.2, 20.1.

IR (ATR, v in cm⁻¹): 3229 (w), 3105 (w), 2361 (w), 1727 (s), 1683 (w) 1640 (s), 1507 (s) 1486 (m), 1451 (m), 1298 (w), 1242 (s), 1156 (m), 1129 (s), 1107 (s), 1086 (s),1026 (w), 860 (m), 700 (s).
MS (ESI) m/z calcd for C₁₇H₁₅NO₃Na 304.1 [M+Na]⁺, found 304.2 [M+Na]⁺.
HRMS (EI) m/z calcd for C₁₇H₁₅NO₃ 281.1052 [M]⁺, found 281.1045 [M]⁺.

2.3.10 (Z)-2-(2-Iodobenzamido)vinyl benzoate 1k



Prepared according to **GP3** from 2-iodo-*N*-(2-oxoethyl)benzamide **3k** (700 mg, 2.42 mmol, 1.0 equiv), triethylamine (0.57 mL, 4.11 mmol, 1.7 equiv) and benzoyl chloride (0.37 mL, 3.14 mmol, 1.3 equiv) in a total of 18 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(2-iodobenzamido)vinyl benzoate **1k** (1.40 g, 58%) as colorless solid. **R**_f (*n*-hexane:EtOAc = 4:1) 0.33.

m.p. 154-157 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.13 – 8.07 (m, 2H), 7.98 – 7.92 (m, 1H), 7.73 (d, J=10.9 Hz, 1H), 7.66 – 7.56 (m, 2H), 7.52 – 7.41 (m, 3H), 7.20 (dd, J=7.9, 1.7 Hz, 1H), 7.16 (d, J=5.1 Hz, 1H), 6.82 (dd, J=10.7 Hz, 5.1, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 165.3, 162.7, 140.6, 140.5, 134.0, 132.1, 130.1, 129.5, 128.8, 128.6, 128.6, 122.4, 108.8, 92.4.

IR (ATR, v in cm⁻¹): 3277 (w), 3112 (w), 2360 (w), 1723 (s), 1687 (w), 1647 (s), 1582 (w), 1502 (s), 1448 (m), 1297 (w), 1249 (s), 1159 (m), 1127 (s), 1093 (s), 1086 (s), 1018 (s), 864 (m), 705 (s).

MS (ESI) m/z calcd for $C_{16}H_{12}INO_{3}Na 416.0 [M+Na]^{+}$, found 416.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{16}H_{12}INO_3$ 392.9862 [M]⁺, found 392.9851 [M]⁺.

2.3.11 (Z)-2-(3-Methylbenzamido)vinyl benzoate 11



Prepared according to **GP3** from 3-methyl-*N*-(2-oxoethyl)benzamide **3I** (719 mg, 4.06 mmol, 1.0 equiv), triethylamine (0.96 mL, 6.90 mmol, 1.7 equiv) and benzoyl chloride (0.61 mL, 5.28 mmol, 1.3 equiv) in a total of 18 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(3-methylbenzamido)vinyl benzoate **1I** (590 mg, 62%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.33.

m.p. 126-127 °C.

¹H NMR (400 MHz, CDCl₃) δ = 8.20 – 8.03 (m, 2H), 7.94 (d, J=10.8 Hz, 1H), 7.75 – 7.59 (m, 3H), 7.52 (dd, J=8.4, 7.1 Hz, 2H), 7.43 – 7.36 (m, 2H), 7.10 (d, J=5.1 Hz, 1H), 6.86 (dd, J=10.7, 5.1 Hz, 1H), 2.44 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ = 164.2, 162.7, 139.0, 134.0, 133.4, 133.2, 130.0, 128.9, 128.8, 128.2, 124.0, 121.8, 109.6, 21.5.

IR (ATR, v in cm⁻¹): 3290 (w), 3067 (w), 2360 (w), 1724 (s), 1695 (w), 1635 (m), 1585 (w), 1507 (s), 1477 (m), 1364 (w), 1261 (s), 1247 (s), 1186 (m), 1143 (s), 1116 (s), 1091 (s), 810 (m), 736 (m), 700 (s).

MS (ESI) m/z calcd for C₁₇H₁₅NO₃Na 304.1 [M+Na]⁺, found 304.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{17}H_{15}NO_3$ 281.1052 [M]⁺, found 281.1048 [M]⁺.

2.3.12 (Z)-2-(Furan-2-carboxamido)vinyl benzoate 1m



Prepared according to **GP3** from *N*-(2,2-dimethoxyethyl)furan-2-carboxamide **3m** (394 mg, 2.57 mmol, 1.0 equiv), triethylamine (607 μ L, 7.80 mmol, 1.7 equiv) and benzoyl chloride (388 μ L, 3.34 mmol, 1.3 equiv) in a total of 10 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(furan-2-carboxamido)vinyl benzoate **1m** (474 mg, 72 %) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.29.

m.p. 133-135 °C.

¹H NMR (400 MHz, CDCl₃) δ = 8.19 (s, 1H), 8.17 – 8.12 (m, 2H), 7.71 – 7.61 (m, 1H), 7.58 – 7.50 (m, 3H), 7.28 – 7.23 (m, 1H), 7.11 (d, J=5.0 Hz, 1H), 6.79 (dd, J=10.9, 5.1 Hz, 1H), 6.58 (dd, J=3.5, 1.8 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 162.7, 154.7, 147.1, 144.8, 134.0, 130.1, 128.9, 128.8, 121.9, 116.2, 112.8, 108.4.

IR (ATR, v in cm⁻¹): 3243 (w), 3118 (w), 2361 (w), 1718 (m), 1692 (w), 1645 (s), 1564 (m), 1515 (s), 1453 (w), 1304 (m), 1252 (s), 1184 (s), 1146 (s), 1116 ()s), 1096 (s), 1022 (m), 947 (m), 833 (w), 706 (s).

MS (ESI) m/z calcd for $C_{14}H_{14}NO_4Na 286.1 [M+Na]^+$, found 279.9 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{14}H_{11}NO_4$ 257.0688 [M]⁺, found 257.0688 [M]⁺.

2.3.13 (Z)-2-(Cyclohexanecarboxamido)vinyl benzoate 1n



Prepared according to **GP3** from *N*-(2-oxoethyl)cyclohexanecarboxamide **3n** (747 mg, 4.41 mmol, 1.0 equiv), triethylamine (1.04 mL, 7.50 mmol, 1.7 equiv) and benzoyl chloride (0.67 mL, 5.73 mmol, 1.3 equiv) in a total of 18 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-(cyclohexanecarboxamido)vinyl benzoate **1n** (1.03 g, 85%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.37.

m.p. 170-173 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.16 – 8.04 (m, 2H), 7.70 – 7.61 (m, 1H), 7.58 – 7.47 (m, 2H), 7.23 (s, 1H), 6.97 (d, J=5.1 Hz, 1H), 6.66 (dd, J=10.8, 5.1 Hz, 1H), 2.22 (tt, J=11.7, 3.6 Hz, 1H), 2.02 – 1.89 (m, 2H), 1.88 – 1.78 (m, 2H), 1.74 – 1.66 (m, 1H), 1.61 – 1.45 (m, 2H), 1.40 – 1.17 (m, 3H).

¹³C NMR (101 MHz, CDCl₃) δ = 172.9, 162.8, 133.9, 130.0, 128.9, 128.8, 120.9, 109.3, 45.5, 29.6, 25.7, 25.7.

IR (ATR, v in cm⁻¹): 3261 (w), 2934 (m), 2852 (w), 2360 (w), 1727 (s), 1695 (w), 1645 (s), 1602 (w), 1513 (s), 1450 (m), 1316 (w), 1251 (s), 1244 (s), 1201 (s), 1119 (s), 1090 (s), 1026 (m), 888 (m), 701 (s).

 $\textbf{MS} \ (\text{ESI}) \ \text{m/z} \ \text{calcd for} \ C_{16}H_{19}\text{NO}_3\text{Na} \ 296.1 \ [\text{M+Na}]^+, \ \text{found} \ 296.2 \ [\text{M+Na}]^+.$

HRMS (EI) m/z calcd for $C_{16}H_{19}NO_3$ 273.1365 [M]⁺, found 273.1351 [M]⁺.

2.3.14 (Z)-2-Benzamidovinyl pivalate 2a



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (721 mg, 4.42 mmol, 1.0 equiv), triethylamine (1.04 mL, 7.51 mmol, 1.7 equiv) and pivaloyl chloride (0.71 mL, 5.75 mmol, 1.3 equiv) in a total of 20 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl pivalate **2a** (609 mg, 56%) as colorless solid. Analytical data are in accordance with those previously reported.^[6]

R_f (*n*-hexane:EtOAc = 4:1) 0.45.

m.p. 93 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.94 – 7.70 (m, 3H), 7.61 – 7.54 (m, 1H), 7.53 – 7.42 (m, 2H), 6.90 (d, J=5.0 Hz, 1H), 6.75 (dd, J=10.6 Hz, 5.0 Hz, 1H), 1.32 (s, 9H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 174.1, 163.6, 133.4, 132.4, 129.1, 127.1, 122.0, 108.9, 39.2, 27.3.

IR (ATR, v in cm⁻¹): 3345 (w), 2984 (w), 1741 (s), 1687 (w), 1645 (s), 1503 (s), 1478 (s), 1395 (w), 1364 (w), 1272 (s), 1124 (s), 1026 (w), 929 (w), 885 (m), 751 (m), 717 (m), 694 (m).
MS (ESI) m/z calcd for C₁₄H₁₇NO₃Na 270.1 [M+Na]⁺, found 270.1 [M+Na]⁺
HRMS (EI) m/z calcd for C₁₄H₁₇NO₃ 247.1208 [M]⁺, found 247.1206 [M]⁺.

2.3.15 (Z)-2-Benzamidovinyl acetate 2b



To a stirred solution of triethylamine (1.17 mL, 8.43 mmol, 1.7 equiv), 4-dimethylaminopyridine (122 mg, 0.992 mmol, 0.2 equiv) and acetic anhydride (0.58 mL, 7.44 mmol, 1.3 equiv) in dichlormethane (10 mL) was added dropwise a solution of the aldehyde **3a** (810 mg, 4.96 mmol, 1.0 equiv) in dichlormethane (10 mL). The reaction mixture was stirred for 3 h at room temperature. After TLC analysis showed complete consumption of the aldehyde, saturated NaHCO₃ solution was added (20 mL). The organic layers were separated and the aqueous phase was extracted with dichlormethane (2x 30 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 9:1 \rightarrow 4:1) afforded (*Z*)-2-benzamidovinyl acetate **2b** (572 mg, 56%) as colorless solid. Analytical data are in accordance with those previously reported.^[6]

R_f (*n*-hexane:EtOAc = 4:1) 0.22.

m.p. 81 °C.

¹**H NMR** (400 MHz CDCl₃) δ = 7.97 – 7.78 (m, 3H), 7.60 – 7.51 (m, 1H), 7.52 – 7.43 (m, 2H), 6.90 (d, *J*=5.2 Hz, 1H), 6.71 (dd, *J*=10.7, 5.1 Hz, 1H), 2.22 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 166.7, 164.0, 133.4, 132.4, 128.9, 127.3, 121.5, 108.6, 20.8.

IR (ATR, v in cm⁻¹): 3255 (w), 3206 (w), 3221 (w), 1750 (m), 1702 (w), 1640 (s), 1603 (w), 1579 (w), 1514 (s), 1484 (s), 1362 (m) 1294 (m), 1207 (s), 1147 (s), 1116 (s), 1040 (m), 1028 (m), 878 (m), 756 (m), 682 (m).

MS (ESI) m/z calcd for $C_{11}H_{11}NO_3Na 228.1 [M+Na]^+$, found 228.1 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{11}H_{11}NO_3$ 205.0739 [M]⁺, found 205.0740 [M]⁺.

2.3.16 (Z)-2-Benzamidovinyl propionate 2c



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and propionyl chloride (90 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl propionate **2c** (21 mg, 19%) as colorless solid. **R**_f (*n*-hexane:EtOAc = 4:1) 0.23.

m.p. 85.3 °C

¹H NMR (400 MHz, CDCl₃) δ = 7.84 – 7.81 (m, 1H), 7.60 – 7.54 (m, 1H), 7.49 (t, J = 7.5 Hz, 1H), 6.93 (d, J = 5.1 Hz, 1H), 6.73 (dd, J = 10.7, 5.1 Hz, 1H), 2.52 (q, J = 7.5 Hz, 1H), 1.24 (t, J = 7.5 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ = 170.3, 163.9, 133.5, 132.4, 129.0, 127.3, 121.6, 108.6, 27.4, 9.0. IR (ATR, v in cm⁻¹): 3356 (w), 2979 (w), 2919 (w), 1751 (s), 1690 (w), 1642 (s), 1582 (w), 1505 (m), 1482 (s), 1448 (w), 1345 (m), 1291 (m), 1134 (s), 1113 (s),1023 (s), 901 (m), 873 (m), 705 (s), 600 (s). MS (ESI) m/z calcd C₁₂H₁₂NO₃ 218.1 [M-H]⁻, found 218.0 [M-H]⁻. HRMS (EI) m/z calcd C₁₂H₁₃NO₃ 219.0895 [M]⁺, found 219.0890 [M]⁺.

2.3.17 (Z)-2-Benzamidovinyl butyrate 2d



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and butyryl chloride (100 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (Z)-2-benzamidovinyl butyrate **2d** (23 mg, 19%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.29.

m.p. 62 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.83 (d, *J* = 7.2 Hz, 3H), 7.56 (t, *J* = 7.4 Hz, 1H), 7.49 (t, *J* = 7.4 Hz, 2H), 6.93 (d, *J* = 5.1 Hz, 1H), 6.72 (dd, *J* = 10.7, 5.1 Hz, 1H), 2.47 (t, *J* = 7.4 Hz, 2H), 1.79 – 1.68 (m, 2H), 1.01 (t, *J* = 7.4 Hz, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 169.4, 163.9, 133.5, 132.4, 129.0, 127.3, 121.5, 108.6, 35.9, 18.4, 13.8. **IR** (ATR, v in cm⁻¹): 3351 (m), 3116 (w), 2965 (w), 1752 (s), 1689 (m), 1642 (s), 1603 (m), 1582 (w), 1507 (m), 1481 (s), 1415 (m), 1352 (m), 1289 (m), 1117 (s), 1075 (s), 1001 (m), 941 (m), 904 (m), 879 (m), 796 (m), 756 (m), 713 (s), 698 (m). $\label{eq:ms} \begin{array}{l} \textbf{MS} \mbox{ (ESI) } m/z \mbox{ calcd } C_{13}H_{14}NO_3 \mbox{ 232.1 } [M-H]^-, \mbox{ found } 232.0 \mbox{ [M-H]}^-. \\ \\ \textbf{HRMS} \mbox{ (EI) } m/z \mbox{ calcd } C_{13}H_{15}NO_3 \mbox{ 233.1052 } [M]^+, \mbox{ found } 233.1044 \mbox{ [M]}^+. \end{array}$

2.3.18 (Z)-2-Benzamidovinyl 2-methylbenzoate 2e



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 2-methylbenzoyl chloride (130 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (Z)-2-benzamidovinyl 2-methylbenzoate **2e** (44 mg, 32%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.40.

m.p. 101 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.98 (d, *J* = 7.7 Hz, 1H), 7.94 (s, 1H), 7.83 (d, *J* = 7.4 Hz, 2H), 7.56 (t, *J* = 7.3 Hz, 1H), 7.48 (dd, *J* = 10.2, 4.5 Hz, 3H), 7.33 (dd, *J* = 7.3, 4.2 Hz, 2H), 7.11 (d, *J* = 5.1 Hz, 1H), 6.85 (dd, *J* = 10.7, 5.1 Hz, 1H), 2.67 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ = 163.9, 163.2, 141.1, 133.4, 133.1, 132.4, 132.2, 130.8, 129.0, 128.2, 127.3, 126.2, 121.8, 109.3, 22.0.

IR (ATR, v in cm⁻¹): 3239 (w), 1726 (s), 1640 (m), 1602 (w), 1579 (w), 1517 (s), 1486 (m), 1379 (w), 1298 (m), 1233 (s), 1153 (m), 1137 (m), 1117 (s), 1066 (s), 913 (w), 861 (m), 800 (w), 733 (m), 693 (m).

MS (ESI) m/z calcd C₁₇H₁₄NO₃ 280.1 [M-H]⁻, found 280.0 [M-H]⁻.

HRMS (EI) m/z calcd C₁₇H₁₅NO₃ 281.1052 [M]⁺, found 281.1043 [M]⁺.

2.3.19 (Z)-2-Benzamidovinyl 4-methylbenzoate 2f



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 4-methylbenzoyl chloride (130 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (Z)-2-benzamidovinyl 4-methylbenzoate **2f** (71 mg, 51%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.40.

m.p. 160 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.99 (d, *J* = 8.1 Hz, 2H), 7.95 (d, *J* = 10.4 Hz, 1H), 7.86 (d, *J* = 7.4 Hz, 2H), 7.58 (t, *J* = 7.3 Hz, 1H), 7.51 (t, *J* = 7.5 Hz, 2H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.09 (d, *J* = 5.1 Hz, 1H), 6.85 (dd, *J* = 10.7, 5.1 Hz, 1H), 2.45 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ = 163.9, 162.8, 145.0, 133.6, 132.4, 130.1, 129.7, 129.1, 127.3, 126.07, 122.0, 109.4, 21.9.

IR (ATR, v in cm⁻¹): 3386 (w), 3112 (w), 1708 (m), 691 (m), 1664 (s), 1609 (m), 1501 (m), 1478 (s), 1281 (w), 1261 (s), 1249 (s), 1178 (m), 1112 (s), 1093 (s), 1016 (m), 839 (w), 748 (m), 709 (s), 603 (s).

MS (ESI) m/z calcd $C_{17}H_{14}NO_3$ 280.1 [M-H]⁻, found 280.1 [M-H]⁻.

HRMS (EI) m/z calcd C₁₇H₁₅NO₃ 281.1052 [M]⁺, found 281.1033 [M]⁺.

2.3.20 (Z)-2-Benzamidovinyl 4-(tert-butyl)benzoate 2g



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 4-(*tert*-butyl)benzoyl chloride (200 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (Z)-2-benzamidovinyl 4-(*tert*-butyl)benzoate **2g** (62 mg, 38%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.45.

m.p. 89 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.03 (d, J = 8.4 Hz, 3H), 7.85 (d, J = 7.3 Hz, 2H), 7.59 – 7.47 (m, 5H), 7.09 (d, J = 5.1 Hz, 1H), 6.83 (dd, J = 10.6, 5.1 Hz, 1H), 1.36 (s, 9H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 164.0, 162.7, 157.9, 133.5, 132.4, 129.9, 129.0, 127.3, 125.9, 122.0, 109.3, 35.4, 31.2.

IR (ATR, v in cm⁻¹): 3398 (m), 2965 (m), 1707 (m), 1689 (m), 1664 (m), 1606 (m), 1515 (m), 1479 (m), 1409 (w), 1364 (w), 1263 (s), 1186 (m), 1145 (m), 1115 (s), 1015 (m), 923 (m), 853 (m), 768 (m), 747 (w), 701 (s).

MS (ESI) m/z calcd $C_{20}H_{20}NO_3$ 322.1 [M-H]⁻, found 322.1 [M-H]⁻.

HRMS (EI) m/z calcd $C_{20}H_{21}NO_3$ 323.1521 [M]⁺, found 323.1521 [M]⁺.

2.3.21 (Z)-2-Benzamidovinyl 4-methoxybenzoate 2h



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 4-methoxybenzoyl chloride (140 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (Z)-2-benzamidovinyl 4-methoxybenzoate **2h** (89 mg, 60%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.43.

m.p. 130 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.08 – 8.03 (m, 2H), 7.98 (d, *J* = 10.4 Hz, 1H), 7.85 (d, *J* = 7.3 Hz, 2H), 7.57 (dd, *J* = 8.5, 6.2 Hz, 1H), 7.50 (t, *J* = 7.5 Hz, 2H), 7.07 (d, *J* = 5.1 Hz, 1H), 6.98 (d, *J* = 8.9 Hz, 2H), 6.82 (dd, *J* = 10.6, 5.1 Hz, 1H), 3.88 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 164.2, 163.9, 162.4, 133.5, 132.4, 132.2, 129.0, 127.3, 122.0, 121.0, 114.2, 109.1, 55.7.

IR (ATR, v in cm⁻¹): 3276 (w), 3029 (w), 1713 (m), 1690 (m), 1650 (m), 1605 (m), 1580 (m), 1511 (s), 1487 (m), 1461 (m), 1370 (w), 1321 (w), 1255 (s), 1184 (m), 1168 (m), 1152 (s), 1118 (s), 1098 (s), 1019 (s), 862 (w), 848 (m), 794 (m), 758 (m), 721 (w), 687(s).

MS (ESI) m/z calcd $C_{17}H_{14}NO_4$ 296.1 [M-H]⁻, found 296.0 [M-H]⁻.

HRMS (EI) m/z calcd $C_{17}H_{15}NO_4$ 297.1001 [M]⁺, found 297.0999 [M]⁺.

2.3.22 (Z)-2-Benzamidovinyl 4-fluorobenzoate 2i



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 4-fluorobenzoyl chloride (159 mg, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl 4-fluorobenzoate **2i** (100 mg, 70%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.38. **m.p.** 177 °C. ¹**H NMR** (400 MHz, CDCl₃) δ = 8.09– 8.02 (m, 2H), 7.87 (d, *J* = 10.1 Hz, 1H), 7.78 (d, *J* = 7.3 Hz, 2H), 7.51 (t, *J* = 7.4 Hz, 1H), 7.43 (t, *J* = 7.4 Hz, 2H), 7.12 (t, *J* = 8.6 Hz, 2H), 7.00 (d, *J* = 5.1 Hz, 1H), 6.78 (dd, *J* = 10.7, 5.1 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 167.7, 165.1, 164.0, 161.8, 133.4, 132.7, 132.6, 132.5, 129.1, 127.3, 125.1, 121.8, 116.3, 116.1, 109.6.

¹⁹**F {H} NMR** (376 MHz, CDCl₃) δ = 103.5.

IR (ATR, v in cm⁻¹): 3262 (w), 3115 (w), 1722 (s), 1691 (m), 1641 (m), 1578 (w), 1519 (m), 1478 (s), 1298 (w), 1258 (s), 1229 (s), 1146 (s), 1116 (s), 1089 (s), 853 (m), 799 (w), 759 (s), 680 (s), 606 (s).

MS (ESI) m/z calcd C₁₆H₁₁FNO₃ 284.1 [M-H]⁻, found 284.0 [M-H]⁻.

HRMS (EI) m/z calcd C₁₆H₁₂FNO₃ 285.0801 [M]⁺, found 285.0817 [M]⁺.

2.3.23 (Z)-2-Benzamidovinyl 4-chlorobenzoate 2j



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 4-chlorobenzoyl chloride (130 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl 4-chlorobenzoate **2j** (109 mg, 72%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.37.

m.p. 143 °C.

¹H NMR (400 MHz, CDCl₃) δ = 8.06 – 8.02 (m, 2H), 7.94 (d, J = 10.3 Hz, 1H), 7.85 (d, J = 7.3 Hz, 2H), 7.61 – 7.56 (m, 1H), 7.51 (t, J = 8.2 Hz, 4H), 7.07 (d, J = 5.1 Hz, 1H), 6.86 (dd, J = 10.7, 5.1 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 164.0, 161.9, 140.7, 133.4, 132.5, 131.4, 129.3, 129.1, 127.3, 127.3, 121.8, 109.8.

IR (ATR, v in cm⁻¹): 3268 (w), 3115 (w), 1732 (s), 1694 (m), 1641 (s), 1594 (m), 1578 (w), 1517 (s), 1484 (s), 1401 (m), 1256 (s), 1149 (s), 1116 (s), 1089 (s), 1013 (s), 913 (w), 8423 (m), 752 (s), 692 (s), 678 (s). **MS** (ESI) m/z calcd C₁₆H₁₁CINO₃ 300.1 [M-H]⁻, found 300.0 [M-H]⁻.

HRMS (EI) m/z calcd $C_{16}H_{12}CINO_3$ 301.0506 [M]⁺, found 301.0521 [M]⁺.

2.3.24 (Z)-2-Benzamidovinyl 4-bromobenzoate 2k



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 4-bromorobenzoyl chloride (130 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl 4-bromobenzoate **2k** (119 mg, 69%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.45.

m.p. 139 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.00 (d, *J* = 10.3 Hz, 1H), 7.95 (d, *J* = 8.4 Hz, 2H), 7.83 (d, *J* = 7.5 Hz, 2H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.57 (t, *J* = 7.3 Hz, 1H), 7.49 (t, *J* = 7.5 Hz, 2H), 7.05 (d, *J* = 5.0 Hz, 1H), 6.84 (dd, *J* = 10.6, 5.1 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 164.0, 162.1, 133.4, 132.45, 132.3, 131.4, 129.3, 129.0, 127.7, 127.3, 121.7, 109.7.

IR (ATR, v in cm⁻¹): 3266 (w), 3115 (w), 1732 (s), 1695 (m), 1641 (s), 1589 (m), 1515 (s), 1487 (s), 1398 (m), 1258 (s), 1149 (s), 1116 (s), 1092 (s), 1066 (s), 1011 (s), 913 (w), 839 (m), 749 (s), 692 (s), 675 (s). MS (ESI) m/z calcd C16H11BrNO3 344.0 [M-H]⁻, found 344.0 [M-H]⁻.

HRMS (EI) m/z calcd C₁₆H₁₂BrNO₃ 345.0001 [M]⁺, found 344.9990 [M]⁺.

2.3.25 (Z)-2-Benzamidovinyl 3-methylbenzoate 21



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 3-methylbenzoyl chloride (130 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl 3-methylbenzoate **2l** (116 mg, 82%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.36.

m.p. 128 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.97 (d, *J* = 10.0 Hz, 1H), 7.88 (dd, *J* = 15.3, 9.5 Hz, 4H), 7.61 – 7.55 (m, 1H), 7.53 – 7.44 (m, 3H), 7.40 (t, *J* = 7.5 Hz, 1H), 7.09 (d, *J* = 5.1 Hz, 1H), 6.86 (dd, *J* = 10.7, 5.1 Hz, 1H), 2.44 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 163.9, 162.9, 138.8, 134.8, 133.5, 132.4, 130.7, 129.1, 128.8, 128.8, 127.3, 127.1, 122.0, 109.5, 21.5.

IR (ATR, v in cm⁻¹): 3247 (w), 1731 (s), 1686 (m), 1641 (s), 1602 (w), 1580 (w), 1516 (s), 1486 (m), 1380 (w), 1325 (w), 1265 (s), 1195 (s), 1151 (m), 1118 (s), 1099 (m), 1076 (s), 1039 (m), 927 (w), 894 (m), 848 (w), 799 (w), 757 (w), 738 (s), 689 (s).

MS (ESI) m/z calcd C₁₇H₁₄NO₃ 280.1 [M-H]⁻, found 280.0 [M-H]⁻.

HRMS (EI) m/z calcd C₁₇H₁₅NO₃ 281.1052 [M]⁺, found 281.1054 [M]⁺.

2.3.26 (Z)-2-Benzamidovinyl 3-methoxybenzoate 2m



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and 3-methoxybenzoyl chloride (140 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (*Z*)-2-benzamidovinyl 3-methoxybenzoate **2m** (90 mg, 60%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.33.

m.p. 118 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.04 (d, *J* = 10.5 Hz, 1H), 7.84 (d, *J* = 7.3 Hz, 2H), 7.67 (d, *J* = 7.7 Hz, 1H), 7.60 - 7.53 (m, 2H), 7.47 (t, *J* = 7.6 Hz, 2H), 7.40 (t, *J* = 8.0 Hz, 2H), 7.16 (dd, *J* = 8.2, 2.6 Hz, 1H), 7.06 (d, *J* = 5.1 Hz, 1H), 6.83 (dd, *J* = 10.6, 5.1 Hz, 1H), 3.86 (s, *J* = 11.4 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ = 164.0, 162.6, 159.9, 133.4, 132.4, 130.0, 129.9, 129.0, 127.3, 122.2, 121.9, 120.2, 114.8, 109.5, 55.6.

IR (ATR, v in cm⁻¹): 3307 (m), 3125 (w), 1729 (s), 1694 (m), 1640 (s), 1609 (m), 1584 (m), 1509 (s), 1483 (s), 1432 (m), 1365 (w), 1271 (s), 1247 (m), 1214 (s), 1178 (m), 1146 (s), 1115 (s), 1095 (m), 1054 (s), 909 (m), 883 (m), 811 (w), 798 (m), 745 (s), 713 (m), 680 (m).

MS (ESI) m/z calcd $C_{17}H_{14}NO_4$ 296.1 [M-H]⁻, found 295.9 [M-H]⁻.

HRMS (EI) m/z calcd C₁₇H₁₅NO₄ 297.1001 [M]⁺, found 297.1017 [M]⁺.

2.3.27 (Z)-2-Benzamidovinyl cyclohexanecarboxylate 2n



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and cyclohexanecarbonyl chloride (140 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (Z)-2-benzamidovinyl cyclohexanecarboxylate **2n** (94 mg, 69%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.47.

m.p. 106 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.82 (dd, *J* = 8.4, 7.0 Hz, 3H), 7.60 – 7.54 (m, 1H), 7.53 – 7.47 (m, 2H), 6.92 (d, *J* = 5.1 Hz, 1H), 6.73 (dd, *J* = 10.7, 5.1 Hz, 1H), 2.48 (tt, *J* = 11.3, 3.6 Hz, 1H), 1.99 (dd, *J* = 13.2, 2.9 Hz, 2H), 1.85 – 1.78 (m, 2H), 1.73 – 1.61 (m, 2H), 1.59 – 1.47 (m, 2H), 1.39 – 1.24 (m, 2H).

¹³C NMR (101 MHz, CDCl₃) δ = 171.8, 163.9, 133.5, 132.4, 129.0, 127.3, 121.7, 108.6, 43.0, 29.1, 25.7, 25.4.

IR (ATR, v in cm⁻¹): 3272 (w), 2931 (m), 2856 (w), 1743 (s), 1701 (m), 1647 (m), 1602 (w), 1582 (w), 1514 (s), 1485 (m), 1449 (m), 1377 (m), 1286 (m), 1244 (m), 1125 (s), 1040 (m), 1026 (m), 1001 (m), 933 (w), 892 (m), 845 (w), 801 (m), 742 (w), 694 (s).

MS (ESI) m/z calcd C₁₆H₁₈NO₃ 272.1 [M-H]⁻, found 272.0 [M-H]⁻.

HRMS (EI) m/z calcd $C_{16}H_{19}NO_3$ 273.1365 [M]⁺, found 273.1366 [M]⁺.

2.3.28 (Z)-2-Benzamidovinyl furan-2-carboxylate 20



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and furan-2-carbonyl chloride (100 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 4:1) afforded (Z)-2-benzamidovinyl furan-2-carboxylate **2o** (83 mg, 65%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.19.

m.p. 156 °C.
¹**H NMR** (400 MHz, CDCl₃) δ = 8.06 (d, *J* = 10.1 Hz, 1H), 7.85 (d, *J* = 7.5 Hz, 2H), 7.66 – 7.65 (m, 1H), 7.56 (t, *J* = 7.3 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 2H), 7.35 (d, *J* = 3.5 Hz, 1H), 7.03 (d, *J* = 5.0 Hz, 1H), 6.83 (dd, *J* = 10.7, 5.0 Hz, 1H), 6.58 (dd, *J* = 3.3, 1.4 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 164.0, 154.5, 147.4, 143.3, 133.3, 132.4, 128.9, 127.3, 121.0, 119.9, 112.5, 109.7.

IR (ATR, v in cm⁻¹): 2971 (w), 1737 (s), 1640 (m), 1519 (m), 1467 (w), 1366 (m), 1284 (m), 1227 (m), 1176 (m), 1149 (m), 1117 (s), 1017 (m), 930 (w), 905 (m), 847 (w), 799 (w), 758 (m), 697 (m).

MS (ESI) m/z calcd $C_{14}H_{10}NO_4$ 256.1 [M-H]⁻, found 255.9 [M-H]⁻.

HRMS (EI) m/z calcd C₁₄H₁₁NO₄ 257.0688 [M]⁺, found 257.0684 [M]⁺.

2.3.29 (Z)-2-Benzamidovinyl thiophene-2-carboxylate 2p



Prepared according to **GP3** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and thiophene-2-carbonyl chloride (130 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by column chromatography (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 19:1 \rightarrow 9:1) afforded (Z)-2-benzamidovinyl thiophene-2-carboxylate **2p** (100 mg, 73%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.23.

m.p. 144 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.98 (d, *J* = 10.2 Hz, 1H), 7.94 (d, *J* = 3.5 Hz, 1H), 7.86 (d, *J* = 7.4 Hz, 2H), 7.67 (d, *J* = 4.9 Hz, 1H), 7.58 (dd, *J* = 8.4, 6.2 Hz, 1H), 7.51 (t, *J* = 7.5 Hz, 2H), 7.21 - 7.17 (m, 1H), 7.05 (d, *J* = 5.0 Hz, 1H), 6.84 (dd, *J* = 10.7, 5.0 Hz, 1H).

¹³C NMR (101 MHz, CDCl₃) δ = 163.8, 158.0, 135.0, 133.8, 133.4, 132.5, 131.8, 129.0, 128.5, 127.2, 121.6, 109.5.

IR (ATR, v in cm⁻¹): 3262 (w), 1716 (m), 1689 (m), 1645 (m), 1579 (w), 1515 (m), 1486 (m), 1416 (m), 1354 (m), 1245 (s), 1218 (s), 1149 (m), 1113 (m), 1084 (s), 905 (w), 862 (m), 800 (w), 737 (m), 689 (m).
MS (ESI) m/z calcd C₁₄H₁₁NNaO₃S 296.0 [M+Na]⁺, found 296.0 [M+Na]⁺.

HRMS (EI) m/z calcd $C_{14}H_{11}NO_3S$ 273.0460 [M]⁺, found 273.0461 [M]⁺.

2.4 (*Z*)-Enol sulfonates GENERAL PROCEDURE 4 (GP4)



To a stirred solution of triethylamine (1.7 equiv) and the corresponding sulfonyl chloride (1.3 equiv) in dichlormethane (2 mL/mmol) was added dropwise a solution of the aldehyde **3a** (1.0 equiv) in dichlormethane (2 mL/mmol) over 5 min. The reaction mixture was stirred for 1 h at room temperature. After TLC analysis showed complete consumption of the aldehyde, saturated NaHCO₃ solution was added (20 mL). The organic layers were separated and the aqueous phase was extracted with dichlormethane (2x 30 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by flash chromatography afforded the desired (*Z*)-enol sulfonates **7a-c** as analytically pure product. All enol sulfonates of type **7** tend to decompose upon contact to any type of acid. Therefore, column chromotography was performed with 0.2 vol% NEt₃ as additive. CDCl₃ for NMR spectroscopy was passed through short plug of basic alumina before use.

2.4.1 (Z)-2-Benzamidovinyl benzenesulfonate 8a



Prepared according to **GP4** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and benzenesulfonyl chloride (85 μ L, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by flash chromatography via puriflash XS 420+ machine, HP_15 μ m_F0012 flash column (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 98:2 \rightarrow 80:20) afforded (*Z*)-2-benzamidovinyl benzenesulfonate **7a** (92 mg, 61%) as colorless solid.

R_f (*n*-hexane:EtOAc = 4:1) 0.20.

m.p. 91 °C

¹**H NMR** (400 MHz, CDCl₃) δ = 7.99 – 7.95 (m, 3H), 7.74 – 7.70 (m, 2H), 7.69 – 7.64 (m, 1H), 7.59 – 7.52 (m, 3H), 7.45 (t, J = 7.6 Hz, 2H), 6.85 (dd, J = 10.8, 4.7 Hz, 1H), 6.04 (d, J = 4.7 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 164.0, 135.0, 134.8, 132.7, 132.6, 129.6, 128.9, 128.2, 127.4, 121.4, 114.8.

IR (ATR, v in cm⁻¹): 3300 (m), 3102 (w), 3063 (w), 1692 (m), 1651 (s), 1582 (m), 1508 (m), (1481 (s), 1378 (s), 1282 (s), 1189 (s), 1146 (s), 1111 (m), 988 (s), 913 (w), 810 (s), 728 (m), 676 (s), 633 (s).
MS (ESI) m/z calcd C₁₅H₁₂NO₄S 302.0 [M-H]⁻, found 301.9 [M-H]⁻.
HRMS (EI) m/z calcd C₁₅H₁₃NO₄S 303.0565 [M]⁺, found 303.0557 [M]⁺.

2.4.2 (Z)-2-Benzamidovinyl 4-methylbenzenesulfonate 8b



Prepared according to **GP4** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and *p*-toluenesulfonyl chloride (124 mg, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by flash chromatography via puriflash XS 420+ machine, HP_15 μ m_F0012 flash column (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 98:2 \rightarrow 80:20) afforded (Z)-2- benzamidovinyl 4-methylbenzenesulfonate **7b** (90 mg, 57%) as colorless solid.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.28.

m.p. 80 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.92 (d, *J* = 10.5 Hz, 1H), 7.84 (d, *J* = 8.3 Hz, 2H), 7.74 – 7.70 (m, 2H), 7.56 (t, *J* = 7.4 Hz, 1H), 7.46 (t, *J* = 7.6 Hz, 2H), 7.34 (d, *J* = 8.2 Hz, 2H), 6.84 (dd, *J* = 10.8, 4.7 Hz, 1H), 6.02 (d, *J* = 4.7 Hz, 1H), 2.40 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ = 164.0, 146.2, 132.7, 132.6, 132.0, 130.3, 128.9, 128.3, 127.4, 121.5, 114.7, 21.8.

IR (ATR, v in cm⁻¹): 3314 (m), 1740 (m), 1691 (m), 1651 (s), 1597 (m), 1582 (m), 1507 (m), 1482 (s), 1375 (s), 1305 (w), 1280 (m), 1190 (m), 1178 (m), 1147 (s), 1111 (m), 1091 (s), 990 (s), 910 (w), 810 (m), 789 (m), 747 (m), 715 (w), 683 (m), 665 (m).

MS (ESI) m/z calcd $C_{16}H_{15}NNaO_4S$ 340.1 [M + Na]⁺, found 340.1 [M + Na]⁺.

HRMS (EI) m/z calcd $C_{15}H_{15}NO_4S$ 317.0724 [M]⁺, found 317.0724 [M]⁺.

2.4.3 (Z)-2-Benzamidovinyl 4-fluorobenzenesulfonate 8c



Prepared according to **GP4** from *N*-(2-oxoethyl)benzamide **3a** (82 mg, 0.5 mmol, 1.0 equiv), triethylamine (120 μ L, 0.85 mmol, 1.7 equiv) and *p*-fluorobenzenesulfonyl chloride (127 mg, 0.65 mmol, 1.3 equiv) in a total of 2 mL dichlormethane. Purification by flash chromatography via puriflash

XS 420+ machine, HP_15µm_F0012 flash column (*n*-hexane:EtOAc + 0.2 vol% NEt₃ = 98:2 \rightarrow 80:20) afforded (*Z*)-2-benzamidovinyl 4-fluorobenzenesulfonate **7c** (79 mg, 49%) as colorless solid. **R**_f (*n*-hexane:EtOAc = 4:1) 0.23.

m.p. 100 °C.

¹**H NMR** (400 MHz, CDCl₃) δ = 8.01 (dd, *J* = 8.9, 4.9 Hz, 3H), 7.79 – 7.72 (m, 2H), 7.58 (t, *J* = 7.4 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 2H), 7.31 – 7.21 (m, 2H), 6.89 (dd, *J* = 10.8, 4.7 Hz, 1H), 6.04 (d, *J* = 4.7 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 167.7, 165.1, 164.1, 132.7, 132.6, 131.3, 131.2, 131.0, 130.9, 129.0, 127.4, 121.2, 117.2, 117.0, 114.9.

¹⁹F {H} NMR (376 MHz, CDCl₃) δ = -100.9

IR (ATR, v in cm⁻¹): 3261 (m), 3107 (w), 1739 (m), 1688 (m), 1652 (m), 1591 (m), 1510 (m), 1484 (m), 1411 (w), 1374 (s), 1286 (m), 1232 (m), 1188 (s), 1161 (m), 1148 (s), 1109 (m), 1090 (m), 982 (s), 926 (w), 908 (w), 838 (m), 822 (m), 806 (m), 761 (m), 694 (s), 670 (m).

MS (ESI) m/z calcd $C_{15}H_{13}FNO_4S$ 320.0 [M-H]⁻, found 320.0 [M-H]⁻.

HRMS (EI) m/z calcd $C_{15}H_{12}NO_4S$ 321.0471 [M]⁺, found 321.0461 [M]⁺.





2.5.1 2-(2,2-Dimethoxyethyl)isoindoline-1,3-dione 9



Prepared according to the literature.^[7]

A solution of amino acetaldehyde dimethylacetal **7** (2.18 mL, 20.0 mmol, 1.0 equiv) and phthalic anhydride (2.96 g, 20.0 mmol, 1.0 equiv) in a total of 70 mL toluene was refluxed for 3 h. Afterwards the solvent was removed under reduced pressure. Purification of the crude residue by flash

chromatography (*n*-hexane:EtOAc = 9:1 \rightarrow 4:1) afforded 2-(2,2-dimethoxyethyl)isoindoline-1,3-dione 9 (3.56 mg, 76%) as colorless solid. Analytical data are in accordance with the literature.^[7] **R**_f (*n*-hexane:EtOAc = 4:1) 0.47.

m.p. 108-110°C

¹**H NMR** (400 MHz, CDCl₃) δ = δ 7.92 – 7.78 (m, 2H), 7.76 – 7.64 (m, 2H), 4.76 (t, J = 5.8 Hz, 1H), 3.82 (d, J = 5.8 Hz, 2H), 3.37 (s, 6H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 168.2, 134.1, 132.1, 123.5, 100.1, 53.3, 38.8.

IR (ATR, v in cm⁻¹): 3066 (w), 2947 (w), 1771 (m), 1708 (s), 1469 (m), 1432 (m), 1395 (s), 1372 (m), 1321

(s), 1216 (w), 1191 (m), 1125 (s), 1055 (s), 1039 (s), 1013 (s), 909 (m), 799 (m), 713 (s), 609 (m).

MS (ESI) m/z calcd $C_{12}H_{13}NNaO_4$ 258.1 [M+Na]⁺, found 258.1 [M+Na]⁺.

HRMS (EI) m/z calcd $C_{12}H_{12}NO_4$ 234.0761 [M-H], found 317.0765 [M-H].

2.5.2 2-(1,3-Dioxoisoindolin-2-yl)acetaldehyde 10



Prepared according to a modified procedure.^[7]

To a solution of 2-(2,2-dimethoxyethyl)isoindoline-1,3-dione **9** (1.18 g, 5.0 mmol, 1.0 equiv) in acetonitrile (50 mL) was added HCl (50 mL, 6 M in water). The reaction mixture was stirred at 60 °C for 14 h. Afterwards brine (50 mL) was added and the aqueous solution was extracted with ethylacetate (3x 50 mL). The combined organic layers were dried over Na₂SO₄ and the solvents were removed under reduced pressure. The analytically pure 2-(1,3-dioxoisoindolin-2-yl)acetaldehyde **10** was obatained without further purification as colorless solid (934 mg, 98%). Analytical data are in accordance with the literature.^[7] Aldehyde **10** seems to be more stable than all other aminoaldehyde derivatives. Therefore compound **10** could be fully characterized.

R_f (*n*-hexane:EtOAc = 4:1) 0.15.

m.p. 109-111°C

¹H NMR (400 MHz, CDCl₃) δ = 9.66 (s, 1H), 7.94 – 7.85 (m, 2H), 7.80 – 7.71 (m, 2H), 4.56 (s, 2H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 193.6, 167.6, 134.5, 132.0, 123.8, 47.5.

IR (ATR, v in cm⁻¹): 2937 (w), 2890 (w), 1778 (m), 1705 (s), 1615 (w), 1467 (m), 1405 (s), 1388 (s), 1301

(s), 1191 (m), 1141 (s), 1088 (w), 1016 (s), 871 (s), 773 (s), 713 (s), 597 (w). 530 (m).

MS (ESI) m/z calcd C₁₁H₁₁NNaO₄ 244.1 [M + Na + MeOH]⁺, found 243.9 [M + Na + MeOH]⁺.

HRMS (EI) m/z calcd $C_{10}H_7NO_3$ 189.0426 [M]⁺, found 189.0439 [M]⁺.

2.5.3 (E/Z)-2-(1,3-Dioxoisoindolin-2-yl)vinyl acetate 11a



To a stirred solution of triethylamine (0.55 mL, 4.0 mmol, 4.0 equiv), 4-dimethylaminopyridine (25 mg, 0.2 mmol, 0.2 equiv) and acetic anhydride (0.19 mL, 2.0 mmol, 2.0 equiv) in dichlormethane (6 mL) was added 2-(1,3-dioxoisoindolin-2-yl)acetaldehyde **10** (189 mg, 1.0 mmol, 1.0 equiv) in one portion. The reaction mixture was stirred for 16 h at room temperature. After TLC analysis showed complete consumption of the aldehyde, saturated NaHCO₃ solution was added (6 mL). The organic layers were separated and the aqueous phase was extracted with dichlormethane (2x 6 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by flash chromatography via puriflash XS 420+ machine, HP_15µm_F0012 flash column (*n*-hexane:CH₂Cl₂ = 90:10 \rightarrow 20:80) afforded (*E*/*Z*)-2-(1,3-dioxoisoindolin-2-yl)vinyl acetate **11a** (114 mg, 49%, *E:Z* = 48:52) as yellow solid (*E*-isomer) and colorless solid (*Z*-isomer). Separation of both isomers could be achieved by flash column chromatography with the above given conditions.

(E)-Isomer:

 \mathbf{R}_{f} (*n*-hexane:EtOAc = 4:1) 0.30

m.p. 149-150°C.

¹**H NMR** (400 MHz CDCl₃) δ = 8.40 (d, J=12.0 Hz, 1H), 7.94 – 7.81 (m, 2H), 7.79 – 7.66 (m, 2H), 6.88 (d, J=11.9 Hz, 1H), 2.19 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 167.8, 165.8, 134.6, 132.7, 131.8, 123.8, 108.7, 20.7.

IR (ATR, v in cm⁻¹): 3136 (w), 1780 (w), 1752 (m), 1725 (s), 1609 (w), 1469 (w), 1392 (s), 1374 (s), 1306 (m), 1199 (s), 1144 (s), 1089 (s), 991 (s), 898 (s), 789 (m), 710 (s), 626 (m), 566 (w), 529 (s).
MS (ESI) m/z calcd for C₁₂H₉NO₄Na 254.2 [M+Na]⁺, found 253.9 [M+Na]⁺.
HRMS (EI) m/z calcd for C₁₂H₉NO₄ 231.0532 [M]⁺, found 231.0527 [M]⁺.

(Z)-Isomer:

R_f (*n*-hexane:EtOAc = 4:1) 0.21

m.p. 105-106°C.

¹**H NMR** (400 MHz CDCl₃) δ = 7.92 – 7.85 (m, 2H), 7.79 – 7.72 (m, 2H), 7.31 (d, J=5.0, 1H), 5.83 (d, J=5.0, 1H), 2.14 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 167.0, 165.9, 134.4, 133.1, 132.2, 123.8, 102.6, 20.7.

IR (ATR, v in cm⁻¹): 3110 (w), 3015 (w), 1782 (w), 1755 (m). 1712 (s), 1687 (s), 1469 (w), 1392 (s9, 1366 (s), 1259 (w9, 1201 (s9, 1186 (s), 1128 (m), 1065 (s), 966 (w), 883 (s), 730 (m), 710 (s), 672 (s), 590 (m).
MS (ESI) m/z calcd for C₁₂H₉NO₄Na 254.2 [M+Na]⁺, found 253.9 [M+Na]⁺.
HRMS (EI) m/z calcd for C₁₂H₉NO₄ 231.0532 [M]⁺, found 231.0542 [M]⁺.

2.5.4 (*E/Z*)- 2-(1,3-Dioxoisoindolin-2-yl)vinyl pivalate **11b**



To a stirred solution of triethylamine (0.55 mL, 4.0 mmol, 4.0 equiv) and pivaloyl chloride (0.25 mL, 2.0 mmol 2.0 equiv) in dichlormethane (6 mL) was added 2-(1,3-dioxoisoindolin-2-yl)acetaldehyde **10** (189 mg, 1.0 mmol, 1.0 equiv) in one portion. The reaction mixture was stirred for 16 h at room temperature. After TLC analysis showed complete consumption of the aldehyde, saturated NaHCO₃ solution was added (6 mL). The organic layers were separated and the aqueous phase was extracted with dichlormethane (2x 6 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by flash chromatography via puriflash XS 420+ machine, HP_15µm_F0012 flash column (*n*-hexane:CH₂Cl₂ = 90:10 \rightarrow 40:60) afforded (*E/Z*)- 2-(1,3-dioxoisoindolin-2-yl)vinyl pivalate **11b** (222 mg, 81%, *E:Z* = 71:29) as pale yellow solid (*E*-isomer) and colorless solid (*Z*-isomer). Separation of both isomers could be achieved by flash column chromatography with the above given conditions.

(E)-Isomer:

R_f (*n*Hex:EtOAc = 4:1) 0.61.

m.p. 98-99 °C

¹**H NMR** (400 MHz, CDCl₃) δ = 8.40 (d, J=11.9 Hz, 1H), 7.93 – 7.84 (m, 2H), 7.80 – 7.70 (m, 2H), 6.91 (d, J=11.9 Hz, 1H), 1.28 (s, 9H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 175.3, 165.9, 134.6, 133.2, 131.8, 123.8, 108.4, 38.9, 27.1.

IR (ATR, v in cm⁻¹): 3130 (w), 2973 (w), 1778 (w), 1745 (s), 1724 (s), 1711 (s), 1469 (w), 1385 (s), 1279

(m), 1205 (w), 1146 (s), 1118 (s), 1066 (m), 1015 (m), 996 (m), 923 (s), 881 (m), 756 (w), 713 (s).

MS (ESI) m/z calcd $C_{15}H_{15}NNaO_4$ 296.1 [M+Na]⁺; found 296.0 [M+Na]⁺.

HRMS (EI) m/z calcd C₁₅H₁₅NO₄ 273.1001 [M]⁺; found 273.0987 [M]⁺.

(Z)-Isomer:

R_f (*n*-hexane:EtOAc = 4:1) 0.55.

m.p. 103-106°C.

¹**H NMR** (400 MHz, CDCl₃) δ = 7.95 – 7.86 (m, 2H), 7.79 – 7.72 (m, 2H), 7.35 (d, J=5.1 Hz, 1H), 5.84 (d, J=5.1 Hz, 1H), 1.21 (s, 9H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 174.5, 165.9, 134.5, 133.3, 132.2, 123.8, 102.2, 39.0, 27.0.

IR (ATR, v in cm⁻¹): 3113 (w), 2976 (w), 1780 (w), 1744 (m), 1717 (s), 1464 (m), 1382 (s), 1272 (m),

1244 (m), 1116 (s), 1048 (m), 955 (w), 885 (m), 736 (m), 716 (s), 672 (m), 530 (m).

MS (ESI) m/z calcd C₁₅H₁₅NNaO₄ 296.1 [M+Na]⁺; found 296.0 [M+Na]⁺.

HRMS (EI) m/z calcd C₁₅H₁₅NO₄ 273.1001 [M]⁺; found 273.0992 [M]⁺.

2.5.5 (E/Z)- 2-(1,3-Dioxoisoindolin-2-yl)vinyl benzoate **11c**



To a stirred solution of triethylamine (0.55 mL, 4.0 mmol, 4.0 equiv) and benzoyl chloride (0.23 mL, 2.0 mmol 2.0 equiv) in dichlormethane (6 mL) was added 2-(1,3-dioxoisoindolin-2-yl)acetaldehyde **10** (189 mg, 1.0 mmol, 1.0 equiv) in one portion. The reaction mixture was stirred for 16 h at room temperature. After TLC analysis showed complete consumption of the aldehyde, saturated NaHCO₃ solution was added (6 mL). The organic layers were separated and the aqueous phase was extracted with dichlormethane (2x 6 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by flash chromatography via puriflash XS 420+ machine, HP_15µm_F0012 flash column (*n*-hexane:CH₂Cl₂ = 90:10 \rightarrow 20:80) afforded (*E/Z*)- 2-(1,3-dioxoisoindolin-2-yl)vinyl benzoate **11c** (257 mg, 88%, *E:Z* = 73:27) as pale yellow solid (*E*-isomer) and colorless solid (*Z*-isomer). Separation of both isomers could be achieved by flash column chromatography with the above given conditions.

Configuration of the double bond could be assigned via the ³J coupling constants of the oelfinic protons (11.9 Hz for the *E*- and 5.2 Hz for the *Z*-isomer). Assignment using vincinal coupling constants was verified by single crystal X-ray structures of *E*-11c (CCDC 2180324) and *Z*-11c (CCDC 2180325).

(E)-Isomer:

R_f (*n*-hexane:EtOAc = 4:1) 0.40 **m.p.** >200°C. ¹**H NMR** (400 MHz CDCl₃) δ = 8.69 (d, J=11.9 Hz, 1H), 8.17 – 8.11 (m, 2H), 7.95 – 7.84 (m, 2H), 7.81 – 7.71 (m, 2H), 7.66 – 7.58 (m, 1H), 7.54 – 7.46 (m, 2H), 7.11 (d, J=11.9 Hz, 1H). ¹³**C NMR** (101 MHz, CDCl₃) δ = 165.9, 163.5, 134.7, 133.8, 132.9, 131.9, 128.8, 128.7, 123.9, 109.1. **IR** (ATR, v in cm⁻¹): 3132 (w), 3073 (w), 1778 (w9, 1728 (s), 1712 (s), 1601 (m), 1449 (m), 1384 (s), 1276 (s), 1145 (s), 1036 (m), 1016 (s), 919 (s), 852 (w), 786 (w), 703 (s), 630 (m), 530 (m). **MS** (ESI) m/z calcd for C₁₇H₁₁NO₄Na 316.1 [M+Na]⁺, found 316.0 [M+Na]⁺. **HRMS** (EI) m/z calcd for C₁₇H₁₁NO₄ 293.0688 [M]⁺, found 293.0671 [M]⁺.

(Z)-Isomer:

R_f (*n*-hexane:EtOAc = 4:1) 0.31

m.p. 169-171°C.

¹**H NMR** (400 MHz CDCl₃) δ = 8.12 – 8.00 (m, 2H), 7.98 – 7.88 (m, 2H), 7.85 – 7.71 (m, 2H), 7.65 – 7.51 (m, 2H), 7.49 – 7.37 (m, 2H), 5.99 (d, J=5.2 Hz, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ = 165.9, 162.8, 134.5, 134.0, 132.5, 132.2, 130.4, 128.7, 128.4, 123.9, 102.8.

IR (ATR, v in cm⁻¹): 3093 (w), 3030 (w), 1738 (m), 1705 (s), 1682 (m), 1454 8w), 1397 (m), 1266 (m), 1226 (m), 1176 (m), 1106 (s), 1099 (s), 1078 (m), 893 (w), 879 (s), 738 (m), 705 (s), 529 (m).

MS (ESI) m/z calcd for $C_{17}H_{11}NO_4Na 316.1 [M+Na]^+$, found 316.0 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{17}H_{11}NO_4$ 293.0688 [M]⁺, found 293.0682 [M]⁺.

2.6 *N*-Methylated 2-oxyenamide



2.6.1 *N*-(2,2-Dimethoxyethyl)-*N*-methylbenzamide **13**



Prepared according to a modified procedure.^[1]

Under nitrogen atmosphere *N*-(2,2-dimethoxyethyl)benzamide **5a** (1.05 g, 5.0 mmol, 1.0 equiv) was added in one portion at 0°C to a suspension of sodium hydride (300 mg, 7.5 mmol, 1.5 equiv, 60% in mineral oil) in DMF_{abs} (10 mL). After stirring for 5 min at 0°C, iodomethane (0.35 mL, 5.5 mmol, 1.1 equiv) was added dropwise. The reaction mixture was stirred at room temperature for 1.5 h. After TLC analysis showed complete consumption of the acetale, saturated NaHCO₃ solution was added (10 mL). The aqueous layer was extracted with ethylacetate (3x 20 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by column chromatography (*n*-hexane:EtOAc = $4:1 \rightarrow 7:3$) afforded *N*-(2,2-dimethoxyethyl)-*N*-methylbenzamide **12** (1.09 g, 97%) as colorless liquid. Compound **13** exists as a mixture of different rotamers. NMR signals could not be assigned to individual romatmers.

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.17.

¹**H NMR** (600 MHz, CDCl₃, a mixture of rotamers) δ 7.50 – 7.31 (m, 5H), 4.70 (t, J=5.5 Hz, 0.65H), 4.36 (s, 0.35H), 3.63 (d, J=5.4 Hz, 1.25H), 3.46 (s, 4H), 3.41 – 3.35 (m, 0.75H), 3.26 (s, 2H), 3.13 (s, 1H), 3.03 (s, 2H).

¹³C NMR (111 MHz, CDCl₃, a mixture of rotamers) δ 172.6, 171.8, 136.5, 129.7, 129.5, 128.5, 127.1, 103.5, 103.1, 54.9, 53.2, 50.0, 39.6, 34.5.

IR (ATR, v in cm⁻¹): 2936 (w), 2833 (w), 1630 (s), 1578 (w), 1445 (m), 1398 (s), 1296 (w), 1192 (w), 1125 (s), 1069 (s9, 1025 (s), 978 (m), 932 (w), 789 (m), 719 (m), 699 (s), 553 (w).

MS (ESI) m/z calcd C₁₂H₁₇NNaO₃ 246.1 [M+Na]⁺, found 246.0 [M+Na]⁺.

HRMS (EI) m/z calcd $C_{12}H_{17}NO_3$ 223.1208 [M]⁺, found 223.1197 [M]⁺.

2.6.2 N-Methyl-N-(2-oxoethyl)benzamide S1



Prepared according to **GP2** from *N*-(2,2-dimethoxyethyl)-*N*-methylbenzamide **13** (1.09g, 4.88 mmol, 1.0 equiv) and 6 M HCl (17 mL) in THF (17 mL). Removal of the solvents afforded the crude aldehyde **S1** (543 mg, 63%) as colorless liquid. (Note! Aldehyde **S1** proved to be very unstable. Therefore, the crude aldehyde was subjected directly to the next step). Compound **12** exists as a mixture of different rotamers. NMR signals could not be assigned to individual romatmers.

R_f (n-hexane:EtOAc = 1:1) 0.15.

¹**H NMR** (400 MHz, CDCl₃, a mixture of rotamers) δ 9.91 – 9.47 (m, 1H), 7.53 – 7.32 (m, 5H), 4.44 – 4.04 (m, 2H), 3.39 – 2.85 (m, 3H).

MS (ESI) m/z calcd for $C_{17}H_{11}NO_4Na 200.1 [M+Na]^+$, found 200.0 [M+Na]⁺.

2.6.3 (E/Z)-2-(N-Methylbenzamido)vinyl acetate 12

To a stirred solution of triethylamine (0.72 mL, 5.20 mmol, 1.7 equiv), 4-dimethylaminopyridine (75 mg, 0.61 mmol, 0.2 equiv) and acetic anhydride (0.33 mL, 4.59 mmol, 1.5 equiv) in dichlormethane (12 mL) was added *N*-methyl-*N*-(2-oxoethyl)benzamide **S1** (543 mg, 3.06 mmol, 1.0 equiv) in one portion. The reaction mixture was stirred for 16 h at room temperature. After TLC analysis showed complete consumption of the aldehyde, saturated NaHCO₃ solution was added (10 mL). The organic layers were separated and the aqueous phase was extracted with dichlormethane (2x 10 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by flash chromatography via puriflash XS 420+ machine, HP_15µm_F0012 flash column (*n*-hexane: EtOAc = 99:1 \rightarrow 80:20) afforded (*E*/*Z*)-2-(*N*-methylbenzamido)vinyl acetate **12** (334 mg, 50%, *E:Z* = 27:73) as colorless liquid (*E*-isomer) and a colorless solid (*Z*-isomer). Separation of both isomers could be achieved by flash column chromatography with the above given conditions.

For the *E*-isomer different rotamers exist in solution at ambient temperature. At higher temperature (363 K) a clearly resolved spectrums showing only on single species could be obtained. For the *Z*-isomer, no rotamers were detected at ambient temperature.

Configuration of the double bond could be assigned via the 3 J coupling constants of the oelfinic protons (11.5 Hz for the *E*- and 5.4 Hz for the *Z*-isomer). Assignment using vincinal coupling constants was verified by single crystal X-ray structures of *Z*-12 (CCDC 2180326).

(E)-Isomer:

 R_{f} (*n*-hexane:EtOAc = 4:1) 0.25

¹**H NMR** (600 Hz, 363 K, DMSO-d⁶) δ = 7.61 – 7.35 (m, 5H), 7.11 (d, J=11.5 Hz, 1H), 7.03 (m, 1H), 3.13 (s, 3H), 2.10 (s, 3H).

¹³C NMR (151 MHz, 363 K, DMSO-d⁶) δ = 168.5, 167.5, 134.6, 129.6, 128.0, 126.9, 124.7, 120.4, 32.3, 19.7.

IR (ATR, v in cm⁻¹): 3113 (w), 2949 (w), 1752 (s), 1644 (s), 1489 (w), 1415 (m), 1364 (s), 1318 (m), 1269 (m), 1221 (s), 1178 (m), 1103 (s), 1069 (s), 1081 (m), 998 (m), 908 (s), 790 (m), 726 (s), 700 (s), 595 (m).
MS (ESI) m/z calcd for C₁₂H₁₃NO₃Na 242.1 [M+Na]⁺, found 242.0 [M+Na]⁺.

HRMS (EI) m/z calcd for $C_{12}H_{13}NO_3$ 219.0895 [M]⁺, found 219.0907 [M]⁺.

(Z)-Isomer:

R_f (*n*-hexane:EtOAc = 4:1) 0.18

m.p. 83-85°C.

¹**H NMR** (400 Hz, DMSO-d⁶) δ = 7.62 – 7.24 (m, 5H), 6.61 (d, J=5.4 Hz, 1H), 5.93 (m, 1H), 3.23 (s, 3H), 2.14 (s, 3H).

¹³**C NMR** (101 Hz, DMSO-d⁶) δ = 169.7, 166.8, 135.4, 130.3, 128.2, 127.7, 124.1, 115.2, 34.7, 20.5.

IR (ATR, v in cm⁻¹): 3100 (w), 3016 (w), 1764 (s), 1628 (s), 1577 (w), 1432 (m), 1369 (m), 1354 (s), 1329

(m), 1219 (s), 1174 (m), 1073 (s), 1025 (m), 956 (m), 800 (m), 762 (s), 719 (s), 700 (s), 593 (m).

 $\textbf{MS} \ (ESI) \ m/z \ calcd \ for \ C_{12}H_{13}NO_{3}Na \ 242.1 \ [M+Na]^{+}, \ found \ 242.0 \ [M+Na]^{+}.$

HRMS (EI) m/z calcd for $C_{12}H_{13}NO_3$ 219.0895 [M]⁺, found 219.0875 [M]⁺.

3 COMPUTATIONAL DETAILS

The conformational space for each structure was explored with Grimme's extended tight-binding method (xTB)^[8] and the meta-dynamics package Conformer Rotamer Ensemble Sampling Tool (CREST).^[9] The default parameters were used in combination with the GFN2-FF force field.^[10] As typically a large number of conformers were obtained, a clustering approach was employed to reduce the number of conformers to 30. The remaining structures were then optimized with the M06-2X functional,^[11] Grimme's D3 correction (zero-damping),^[12] and the triple- ζ basis set 6-311+G(d,p). Solvation by dichloromethane was accounted for with the SMD solvation model^[13] and a superfine grid was used for the numerical integration of the density. Vibrational analysis verified that each structure was a minimum. Thermal corrections were obtained from unscaled harmonic vibrational frequencies at the same level of theory for a standard state of 1 mol L⁻¹ and 298.15 K. Entropic contributions to free energies were obtained from partition functions evaluated with Grimme's quasi-harmonic approximation.^[14] This method employs the free-rotor approximation for all frequencies below 100 cm⁻¹, the rigid-rotor-harmonic-oscillator (RRHO) approximation for all frequencies above 100 cm⁻¹, and a damping function to interpolate between the two expressions. Similar results were obtained from partition functions evaluated with Cramer's and Truhlar's quasiharmonic approximation.^[15] Electronic energies were subsequently obtained from single-point calculations employing Neese's domain-based local pair-natural orbital (DLPNO) approach to the CCSD(T) method [DLPNO-CCSD(T)] with the default normalPNO settings,^[16] an extrapolation to the basis set limit as implemented in ORCA using def2-TZVPP and def2-QZVPP as well as appropriate auxiliary basis sets,^[17] and the SMD solvation model for dichloromethane.^[13] The calculations were performed with Gaussian16^[18] and ORCA.^[19]

The optimized geometries for each structure as well as the associated electronic energies and thermal corrections are provided in an additional archive file.

4 NMR DATA



Figure 1: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5a** in CDCl₃.



Figure 2: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5b** in CDCl₃.



Figure 3: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5c** in CDCl₃.



Figure 4: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5d** in CDCl₃.





Figure 6: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5f** in CDCl₃.



Figure 7: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5g** in CDCl₃.





Figure 8: ¹H (400 MHz), ¹³C (126 MHz) NMR and ¹⁹F (376 MHz) NMR spectra of **5h** in CDCl₃.



Figure 9: ${}^{1}H$ (400 MHz) and ${}^{13}C$ (126) NMR spectra of **5i** in CDCl₃.



Figure 10: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5***j* in CDCl₃.



Figure 11: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5k** in CDCl₃.



Figure 12: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5I** in CDCl₃.



Figure 13: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5m** in CDCl₃.



Figure 14: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5n** in CDCl₃.



Figure 15: ¹H (400 MHz) and ¹³C (126) NMR spectra of **50** in CDCl₃.



Figure 16: ¹H (400 MHz) and ¹³C (126) NMR spectra of **5p** in CDCl₃.



Figure 18: ¹H (400 MHz) NMR spectra of **3c** in CDCl₃.



Figure 19: ¹H (400 MHz) NMR spectra of **3d** in CDCl₃.



Figure 20: ¹H (400 MHz) NMR spectra of **3e** in CDCl₃.



Figure 12: ¹H (400 MHz) NMR spectra of **3f** in CDCl₃.



Figure 21: ¹H (400 MHz) NMR spectra of **3g** in CDCl₃.









Figure 23: ¹H (400 MHz) NMR spectra of **3i** in CDCl₃.





Figure 25: ¹H (400 MHz) NMR spectra of **3k** in CDCl₃.





Figure 27: ¹H (400 MHz) NMR spectra of **3m** in CDCl₃.


Figure 28: ¹H (400 MHz) NMR spectra of **3n** in CDCl₃.

Barton Control (Control) Barton C



Figure 29: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1a** in CDCl₃.



Figure 30: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1c** in CDCl₃.



Figure 31: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1d** in CDCl₃.



Figure 32: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1e** in CDCl₃.



Figure 33: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1f** in CDCl₃.





Figure 34: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1g** in CDCl₃.









Figure 35: ¹H (400 MHz), ¹³C (101 MHz) and ¹⁹F (376 MHz) NMR spectra of **1h** in CDCl₃.







Figure 36: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1i** in CDCl₃.



Figure 37: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1j** in CDCl₃.



Figure 38: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1k** in CDCl₃.



Figure 39: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1**I in CDCl₃.





Figure 40: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1m** in CDCl₃.





Figure 41: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **1n** in CDCl₃.



Figure 42: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2a** in CDCl₃.



Figure 43: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2b** in CDCl₃.



Figure 44: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2c** in CDCl₃.



Figure 45: ^1H (400 MHz) and ^{13}C (101 MHz) NMR spectra of 2d in CDCl_3.



Figure 46: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2e** in CDCl₃.



Figure 47: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2f** in CDCl₃.



Figure 48: ^1H (400 MHz) and ^{13}C (101 MHz) NMR spectra of 2g in CDCl_3.



Figure 49: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2h** in CDCl₃.





Figure 50: ¹H (400 MHz), ¹³C (101 MHz) and ¹⁹F (376 MHz) NMR spectra of **2i** in CDCl₃.



Figure 51: ^1H (400 MHz) and ^{13}C (101 MHz) NMR spectra of 2j in CDCl3.



Figure 52: ^1H (400 MHz) and ^{13}C (101 MHz) NMR spectra of 2k in CDCl_3.



Figure 53: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2I** in CDCl₃.



Figure 54: ^1H (400 MHz) and ^{13}C (101 MHz) NMR spectra of 2m in CDCl_3.



Figure 55: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2n** in CDCl₃.



Figure 56: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **20** in CDCl₃.



Figure 57: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **2p** in CDCl₃.



Figure 58; ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **7a** in CDCl₃.



Figure 59: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **7b** in CDCl₃.





Figure 60: ¹H (400 MHz), ¹³C (101 MHz) and ¹⁹F (376 MHz) NMR spectra of **7c** in CDCl₃.


Figure 61: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **8** in CDCl₃.



Figure 62: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **9** in CDCl₃.



Figure 63: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **E-10a** in CDCl₃.



Figure 64: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **Z-10a** in CDCl₃.



Figure 65: ^1H (400 MHz) and ^{13}C (101 MHz) NMR spectra of **Z-10b** in CDCl_3.



Figure 66: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **E-10b** in CDCl₃.









00 190

110 100 f1 (ppm)







Figure 69: ¹H (400 MHz) and ¹³C (101 MHz) NMR spectra of **12** in CDCl₃.



Figure 70: ¹H (400 MHz) NMR spectra of **S1** in CDCl₃.



Figure 71: ¹H (600 MHz) NMR spectra of **E-11** in DMSO-d⁶ at different temperatures.



Figure 72: ¹H (600 MHz) and ¹³C (151) NMR spectra of **E-11** in DMSO-d⁶.



Figure 73: 1 H (400 MHz) and 13 C (101) NMR spectra of **E-11** in DMSO-d⁶.

5 XRAY



Table 1. Crystal data and structure refinement for **1a**. Displacement ellipsoids are shown at the 50% probability level.

Identification code	CCDC 2180323		
Empirical formula	$C_{16}H_{13}NO_3$		
Formula weight	267.27		
Temperature	293(2) К		
Wavelength	1.54184 Å		
Crystal system	Monoclinic		
Space group	P 21/n		
Unit cell dimensions	a = 7.9146(3) α = 90°.		
	b = 19.7402(5) Å β = 108.761(3)°.		
	c = 9.2157(3) Å γ = 90°.		
Volume	1363.32(8) Å ³		
Z	4		
Density (calculated)	1.302 Mg/m ³		
Absorption coefficient	0.743 mm ⁻¹		
F(000)	560		
Crystal size	0.480 x 0.480 x 0.280 mm ³		
Theta range for data collection	4.480 to 61.935°.		
Index ranges	-8<=h<=9, -22<=k<=19, -10<=l<=10		
Reflections collected	5168		
Independent reflections	2126 [R(int) = 0.0275]		
Completeness to theta = 61.935°	99.5 %		
Absorption correction	Semi-empirical from equivalents		
Max. and min. transmission	1.00000 and 0.64017		
Refinement method	Full-matrix least-squares on F ²		
Data / restraints / parameters	2126 / 0 / 182		
Goodness-of-fit on F ²	1.071		
Final R indices [I>2sigma(I)]	R1 = 0.0474, wR2 = 0.1321		
R indices (all data)	R1 = 0.0525, wR2 = 0.1386		
Extinction coefficient	0.0048(12)		
Largest diff. peak and hole	0.138 and -0.153 e.Å ⁻³		



Table 2. Crystal data and structure refinement for *E*-11c. Displacement ellipsoids are shown at the 50% probability level.

Identification code	CCDC 2180324	CCDC 2180324		
Empirical formula	$C_{17} H_{11} NO_4$			
Formula weight	293.27	293.27		
Temperature	150(2) K	150(2) К		
Wavelength	0.71073 Å			
Crystal system	Triclinic			
Space group	P -1			
Unit cell dimensions	a = 7.3631(4) Å	α= 77.411(4)°.		
	b = 8.3022(3) Å	v= 75.849(4)°.		
	c = 11.5152(6) Å	γ = 85.663(3)°.		
Volume	665.97(6) Å ³			
Z	2			
Density (calculated)	1.462 Mg/m ³			
Absorption coefficient	0.106 mm ⁻¹	0.106 mm ⁻¹		
F(000)	304			
Crystal size	0.550 x 0.180 x 0.030	0.550 x 0.180 x 0.030 mm ³		
Theta range for data collection	2.804 to 30.000°.	2.804 to 30.000°.		
Index ranges	-9<=h<=10, -10<=k<=1	-9<=h<=10, -10<=k<=11, -16<=l<=16		
Reflections collected	7764	7764		
Independent reflections	3881 [R(int) = 0.0279]	3881 [R(int) = 0.0279]		
Completeness to theta = 25.242°	99.9 %	99.9 %		
Absorption correction	Semi-empirical from e	Semi-empirical from equivalents		
Max. and min. transmission	1.00000 and 0.70334	1.00000 and 0.70334		
Refinement method	Full-matrix least-squar	Full-matrix least-squares on F ²		
Data / restraints / parameters	3881/0/199	3881/0/199		
Goodness-of-fit on F ²	1.041			
Final R indices [I>2sigma(I)]	R1 = 0.0425, wR2 = 0.2	R1 = 0.0425, wR2 = 0.1063		
R indices (all data)	R1 = 0.0615, wR2 = 0.2	R1 = 0.0615, wR2 = 0.1201		
Extinction coefficient	n/a	n/a		
Largest diff. peak and hole	0.317 and -0.265 e.Å ⁻³	0.317 and -0.265 e.Å ⁻³		



Table 3. Crystal data and structure refinement for **Z-11c**. Displacement ellipsoids are shown at the 50% probability level.

Identification code	CCDC 2180325			
Empirical formula	$C_{17}H_{11}NO_4$	C ₁₇ H ₁₁ NO ₄		
Formula weight	293.27	293.27		
Temperature	150(2) K	150(2) К		
Wavelength	1.54184 Å			
Crystal system	Monoclinic			
Space group	P 21/c			
Unit cell dimensions	a = 11.8563(4) Å	a= 90°.		
	b = 13.8074(4) Å	b= 111.751(4)°.		
	c = 8.8461(3) Å	g = 90°.		
Volume	1345.04(8) Å ³			
Z	4			
Density (calculated)	1.448 Mg/m ³			
Absorption coefficient	0.870 mm ⁻¹	0.870 mm ⁻¹		
F(000)	608			
Crystal size	0.280 x 0.180 x 0.140	0.280 x 0.180 x 0.140 mm ³		
Theta range for data collection	4.014 to 62.580°.	4.014 to 62.580°.		
Index ranges	-13<=h<=13, -15<=k<=	-13<=h<=13, -15<=k<=11, -7<=l<=10		
Reflections collected	5559	5559		
Independent reflections	2132 [R(int) = 0.0262]	2132 [R(int) = 0.0262]		
Completeness to theta = 62.580°	99.1 %	99.1 %		
Absorption correction	Semi-empirical from e	Semi-empirical from equivalents		
Max. and min. transmission	1.00000 and 0.91601	1.00000 and 0.91601		
Refinement method	Full-matrix least-square	Full-matrix least-squares on F ²		
Data / restraints / parameters	2132 / 0 / 200	2132 / 0 / 200		
Goodness-of-fit on F ²	1.042			
Final R indices [I>2sigma(I)]	R1 = 0.0426, wR2 = 0.2	R1 = 0.0426, wR2 = 0.1155		
R indices (all data)	R1 = 0.0444, wR2 = 0.2	R1 = 0.0444, wR2 = 0.1177		
Extinction coefficient	0.0032(6)	0.0032(6)		
Largest diff. peak and hole	0.180 and -0.203 e.Å ^{-;}	0.180 and -0.203 e.Å ⁻³		



Table 3. Crystal data and structure refinement for **Z-12**. Displacement ellipsoids are shown at the 50% probability level.

CCDC 2180326		
C ₁₂ H ₁₃ NO ₃		
219.23		
150(2) К		
1.54184 Å		
Monoclinic		
P 21		
a = 7.5089(4) Å	a= 90°.	
b = 6.6411(4) Å	b= 106.354(6)°.	
c = 11.4915(8) Å	g = 90°.	
549.87(6) Å ³		
2		
1.324 Mg/m ³		
0.790 mm ⁻¹		
232		
0.360 x 0.280 x 0.040 mm ³		
4.009 to 62.599°.		
-8<=h<=8, -7<=k<=7, -13<=l<=11		
2259		
1457 [R(int) = 0.0357]		
98.7 %		
Semi-empirical from equivalents		
1.00000 and 0.50745		
Full-matrix least-squares on F ²		
1457 / 1 / 147		
1.050		
R1 = 0.0537, wR2 = 0.1339		
R1 = 0.0555, wR2 = 0.1374		
0.0(3)		
n/a		
0.244 and -0.269 e.Å ⁻³		
	CCDC 2180326 $C_{12}H_{13}NO_3$ 219.23 150(2) K 1.54184 Å Monoclinic P 21 a = 7.5089(4) Å b = 6.6411(4) Å c = 11.4915(8) Å 549.87(6) Å ³ 2 1.324 Mg/m ³ 0.790 mm ⁻¹ 232 0.360 x 0.280 x 0.040 mm ³ 4.009 to 62.599°. -8<=h<=8, -7<=k<=7, -13<=l<2259 1457 [R(int) = 0.0357] 98.7 % Semi-empirical from equival 1.0000 and 0.50745 Full-matrix least-squares on 1457 / 1 / 147 1.050 R1 = 0.0537, wR2 = 0.1339 R1 = 0.0555, wR2 = 0.1374 0.0(3) n/a 0.244 and -0.269 e.Å ⁻³	

6 **R**EFERENCES

- [1] H. Ueda, M. Yamaguchi, H. Kameya, K. Sugimoto, H. Tokuyama, Org. Lett. 2014, 16, 4948.
- [2] O. Chantarasriwong, B. Jiangchareon, C. K. Putra, W. Suwankrua, W. Chavasiri, *Tetrahedron Lett.* **2016**, *57*, 4807–4811.
- [3] J. F. Hooper, S. Seo, F. R. Truscott, J. D. Neuhaus, M. C. Willis, J. Am. Chem. Soc. 2016, 138, 1630–1634.
- [4] M. Marzi, D. Alloatti, G. Giannini, World Intellectual Property Patent WO 2004/005328 A2, 2004.
- [5] W. J. Greenlee, P. L. Allibone, D. S. Perlow, A. A. Patchett, E. H. Ulm, T. C. Vassil, *J. Med. Chem.* 1985, 28, 434-442.
- [6] S.-C. Krieg, J. Grimmer, P. Kramer, M. Bolte, H. Kelm, G. Manolikakes, *Angew. Chem. Int. Ed.* **2021**, 60, 23667–23671; *Angew. Chem.* **2021**, 133, 23859–23864.
- [7] P. S. Naidu, P. J. Bhuyan, *Tetrahedron Lett.* **2012**, *53*, 426–428.
- [8] C. Bannwarth, E. Caldeweyher, S. Ehlert, A. Hansen, P. Pracht, J. Seibert, S. Spicher, S. Grimme, Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2021, 11, e1493.
- [9] a) S. Grimme, J. Chem. Theory Comput. 2019, 15, 2847–2862; b) P. Pracht, F. Bohle, S. Grimme, Phys. Chem. Chem. Phys. 2020, 22, 7169–7192.
- S. Spicher, S. Grimme, Angew. Chem. Int. Ed. 2020, 59, 15665–15673; Angew. Chem. 2020, 132, 15795–15803.
- [11] Y. Zhao, D. G. Truhlar, *Theor. Chem. Acc.* **2008**, *120*, 215–241.
- [12] S. Grimme, J. Antony, S. Ehrlich, H. Krieg, J. Chem. Phys. 2010, 132, 154104.
- [13] A. V. Marenich, C. J. Cramer, D. G. Truhlar, J. Phys. Chem. B 2009, 113, 6378–6396.
- [14] S. Grimme, *Chem. Eur. J.* **2012**, *18*, 9955–9964.
- [15] R. F. Ribeiro, A. V. Marenich, C. J. Cramer, D. G. Truhlar, J. Phys. Chem. B 2011, 115, 14556– 14562.
- [16] a) F. Neese, A. Hansen, D. G. Liakos, J. Chem. Phys. 2009, 131, 064103; b) F. Neese, F. Wennmohs, A. Hansen, J. Chem. Phys. 2009, 130, 114108; c) C. Riplinger, B. Sandhoefer, A. Hansen, F. Neese, J. Chem. Phys. 2013, 139, 134101; d) C. Riplinger, F. Neese, J. Chem. Phys. 2013, 138, 034106.
- [17] a) F. Weigend, R. Ahlrichs, *Phys. Chem. Chem. Phys.* 2005, *7*, 3297–3305; b) A. Hellweg, C. Hättig, S. Höfener, W. Klopper, *Theor. Chem. Acc.* 2007, *117*, 587–597.

- [18] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, Williams, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, D. J. Fox, Wallingford, CT, **2016**.
- [19] a) F. Neese, Wiley Interdiscip. Rev. Comput. Mol. Sci. 2012, 2, 73–78; b) F. Neese, Wiley Interdiscip. Rev. Comput. Mol. Sci. 2018, 8, e1327.